Document:

EX-10.16

Exhibit 10.16

SETTLEMENT AGREEMENT

	I.	 	PARTIES

     This Settlement Agreement (“Agreement”) is entered into among the United States of America,
acting through the United States Department of Justice, Civil Division, and the United States
Attorney’s Office for the Eastern District of Pennsylvania, the Office of Inspector General
(“OIG-HHS”) of the Department of Health and Human Services (“HHS”), TRICARE Management Activity
(“TMA”) and the United States Office of Personnel Management (“OPM”) (collectively the “United
States”); the Relators as identified in Paragraphs B through E of the Preamble to this Agreement
(“Relators”); and Eli Lilly and Company (“Eli Lilly”). Collectively, all of the above will be
referred to as “the Parties.”

	II.	 	PREAMBLE

     As a preamble to this Agreement, the Parties agree to the following:

     A. At all relevant times, Eli Lilly, an Indiana corporation headquartered in
Indianapolis, Indiana, distributed, marketed and sold pharmaceutical products in the United
States, including a drug sold under the trade name of Zyprexa.

     The qui tam actions identified in Paragraphs (B) through (E) will be referred to
collectively as the “Civil Actions.”

     B. Robert Rudolph (“Rudolph”), Hector Rosado (“Rosado”), and Robert Evan Daywitt
(“Daywitt”) filed a qui tam action in the United States District Court for the Eastern

-1-

 

District of Pennsylvania captioned United States of America ex rel. Robert Rudolph, et al., v.
Eli Lilly and Company, Civil Action No. 03-943. On August 13, 2003, Rudolph, Rosado and Daywitt
filed a first amended complaint, adding relators Bradley Lutz (“Lutz”) and James Wetta (“Wetta”). A
second amended complaint was filed on September 27, 2007, adding relator William Lofing (“Lofing”).

     C. Joseph Faltaous (“Faltaous”) filed a qui tam action in the United States District
Court for the Eastern District of New York captioned United States of America ex rel.
Joseph
Faltaous v. Eli Lilly and Company, Civil Action No. 05-1471. That action was
transferred to the
Eastern District of Pennsylvania as Civil Action No. 06-2909.

     D. Steven Woodward (“Woodward”) filed a qui tam action in the United States
District Court for the Eastern District of Pennsylvania captioned United States ex rel.
Steven
Woodward v. Dr. George B. Jerusalem, Tesse Jerusalem, Bay Psychiatric Services, and Eli
Lilly,
Civil Action No. 06-5526.

     E. Jaydeen Vicente (“Vicente”) filed a qui tam action in the United States District
Court for the Eastern District of Pennsylvania captioned United States of America ex
rel.
Javdeen Vicente v. Eli Lilly and Company, Civil Action No. 07-1791.

     F. Eli Lilly has entered into a plea agreement with the United States Attorney for the
Eastern District of Pennsylvania and the Office of Consumer Litigation of the Department of
Justice and has agreed to plead guilty, pursuant to Fed.R.Crim.P. 11 to specific conduct
described in a plea agreement to be filed in United States v. Eli Lilly and Company
(the “Federal
Criminal Action”).

     G. Eli Lilly will be entering into separate settlement agreements, described in

-2-

 

Paragraph III.1(b) below (hereinafter referred to as the “Medicaid State Settlement Agreements”)
with certain states and the District of Columbia in settlement of the Covered Conduct. States with
which Eli Lilly executes a Medicaid State Settlement Agreement in the form to which Eli Lilly and
the National Association of Medicaid Fraud Control Units (“NAMFCU”) have agreed, or in a form
otherwise agreed to by Eli Lilly and an individual State, shall be defined as “Medicaid
Participating States.”

     H. The United States and the Medicaid Participating States allege that Eli Lilly caused
claims for payment for Zyprexa to be submitted to the Medicaid Program, Title XIX of the Social
Security Act, 42 U.S.C. §§ 1396-1396v (“the Medicaid Program”).

     I. The United States further alleges that Eli Lilly caused claims for payment for
Zyprexa to be submitted to the TRICARE program, 10 U.S.C. §§ 1071-1109; the Federal Employees
Health Benefits Program (“FEHBP”), 5 U.S.C. §§ 8901-8914; and caused purchases of Zyprexa by the
Department of Veterans Affairs (“DVA”), the Bureau of Prisons (“BOP”), the Department of Defense,
the Department of Labor, and the Public Health Service Entities.

     J. The United States contends that it has certain civil claims against Eli Lilly, as
specified in Paragraph III.2 below, for engaging in the following conduct concerning the marketing,
promotion and sale of Zyprexa between September 1999 and
December 31, 2005 (hereinafter referred to
as the “Covered Conduct”):

-3-

 

	 	 	 	 	 
	 

	 	Eli Lilly knowingly promoted the sale and use of Zyprexa
to psychiatrists, other physicians (including primary
care physicians), and other health care professionals
(collectively, “Health Care Professionals”) for certain
uses for which the Food and Drug Administration had not
approved (i.e. “unapproved uses”); Eli Lilly implemented
a marketing strategy to promote Zyprexa to Health Care
Professionals, who treated patients of all ages, for
unapproved uses; Eli Lilly also promoted Zyprexa to
Health Care Professionals treating patients in long term
care facilities for unapproved uses; Eli Lilly
encouraged Health Care Professionals to prescribe
Zyprexa in higher amounts than the recommended dose; the
promotion of Zyprexa for these unapproved uses violated
the Food Drug and Cosmetic Act, 21 U.S.C. § 331 (a) and
21 U.S.C. § 352(f); Eli Lilly, in connection with its
marketing and promotional efforts for Zyprexa, provided
remuneration and other things of value to Health Care
Professionals; and these unapproved uses were not
medically accepted indications for which the United
States and State Medicaid programs provided coverage.
	 	 
	 
	 	 	 	 
	 

	 	As a result of the foregoing alleged conduct, the United
States contends that Eli Lilly knowingly caused false
and/or fraudulent claims to be submitted to the United
States and the Medicaid programs and caused TRICARE, the
FEHBP, the Department of Veterans Affairs, the Bureau of
Prisons, the Department of Defense, the Department of
Labor, and Public Health Service Entities to purchase
Zyprexa for these unapproved uses.	 	 

     K. The United States also contends that it has certain administrative claims against Eli
Lilly as specified in Paragraphs III.4-6 below, for engaging in the Covered Conduct.

     L. This Agreement is made in compromise of disputed claims. This Agreement is neither an
admission of facts or liability by Eli Lilly nor a concession by the United States that its

-4-

 

claims are not well-founded. With the exception of the specific conduct for which Eli Lilly is
pleading guilty as described in the plea agreement filed in connection with the Federal Criminal
action, Eli Lilly expressly denies the allegations of the United States and the Relators as set
forth herein and in the Civil Actions and denies that it has engaged in any wrongful conduct in
connection with the Covered Conduct. Neither this agreement, its execution, nor the performance of
any obligation under it, including any payment, nor the fact of settlement, is intended to be, or
shall be understood as, an admission of liability or wrongdoing, or other expression reflecting
upon the merits of the dispute by Eli Lilly.

     M. To avoid the delay, expense, inconvenience, and uncertainty of protracted litigation
of these claims, the Parties mutually desire to reach a full and final settlement as set forth
below.

	III.	 	TERMS AND CONDITIONS

     1. Subject to the terms and procedures set forth below, Eli Lilly agrees to pay to the
United States the sum of Four Hundred Thirty Eight Million, One Hundred Seventy One Thousand, Five
Hundred Forty Three Dollars and Fifty Eight Cents ($438,171,543.58) plus accrued interest in an
amount of 3% per annum from October 20, 2008 and continuing until and including the day of payment
(the “Federal Settlement Amount”), and — pursuant to the terms of Paragraph III.1.b — agrees to
pay to all of the States and the District of Columbia (which shall be defined, for purposes of this
Agreement, as a State) Three Hundred Sixty One Million, Eight Hundred Twenty Eight Thousand, Four
Hundred Fifty Six Dollars and Forty Two Cents ($361,828,456.42) plus accrued interest in the amount
described in sub-paragraph III.1.b(ii)

-5-

 

below, of which One Million, Four Hundred Thirty Three Thousand, Six Hundred Forty Two Dollars and
Ninety Six Cents ($1,433,642.96) has already been paid to the State of Alaska pursuant to a
separate settlement agreement. The amount of Three Hundred Sixty Million, Three Hundred Ninety Four
Thousand, Eight Hundred Thirteen Dollars and Forty Six Cents ($360,394,813.46) shall be defined as
the “Medicaid State Settlement Amount”.

          (a) The Federal Settlement Amount shall be paid by electronic funds transfer
pursuant to written instructions to be provided by the United States. Eli Lilly agrees to make
this
electronic funds transfer no later than ten (10) business days after the date on which the
Court
accepts Eli Lilly’s guilty plea in connection with the Federal Criminal Action and imposes the
agreed-upon sentence.

          (b) Eli Lilly shall pay the States according to the following terms:

               (i) No later than ten (10) business days following the date on which the Court accepts
Eli Lilly’s guilty plea in connection with the Federal Criminal Action and imposes the agreed-upon
sentence (the “Account Establishment Date”), Eli Lilly shall deposit the Medicaid State Settlement
Amount plus accrued interest in the amount of 3% per annum earned on that amount from October
20, 2008 to the Account Establishment Date into one or more interest-bearing money market or bank
accounts that are held in the name of Eli Lilly but segregated from other Eli Lilly accounts (the
“State Settlement Accounts”).

               (ii) From the State Settlement Accounts, Eli Lilly shall pay (through the mechanism
described below involving the New York State Attorney General’s National Global Settlement Account
(the “NY State Account”)) to each State (with the exception of Alaska, with which Eli Lilly has
reached a separate agreement including this matter) that

-6-

 

becomes a Medicaid
Participating State (as that term is defined above) within the time limits
established in subparagraph III.1.b(iv) below, that State’s share of the Medicaid State Settlement
Amount (as set forth in a communication from NAMFCU to Eli Lilly counsel on January 13, 2009) (the
“Individual State Share”) plus accrued interest on that Individual State Share in the amount of 3%
per annum from October 20, 2008 to the Account Establishment Date plus that State’s pro rata share
of interest accrued in the State Settlement Accounts from the day following the Account
Establishment Date until the date that payment is made to the NY State Account. Eli Lilly shall
execute a Medicaid State Settlement Agreement with any State that executes such an agreement;
provided, however, that Eli Lilly reserves the right not to execute a Medicaid State Settlement
Agreement with any State that is engaged in litigation with Eli Lilly in a matter relating to
Zyprexa. Eli Lilly shall pay the aggregate amount that it owes to the States that become Medicaid
Participating States within 60 days following the Account Establishment Date to the NY State
Account, pursuant to written wire instructions provided by NAMFCU, on the 70th day
following the Account Establishment Date or within two (2) business days following receipt by Eli
Lilly of the written wire instructions, whichever is later.

          (iii) Eli Lilly may, at its sole discretion, waive any rights that it has reserved in
sub-paragraph III.1.b(ii) with respect to the payment of any of the Individual State Shares.

          (iv) Except as otherwise provided in this sub-paragraph, absent Lilly’s consent, no State
may become a Medicaid Participating State if it has not executed a Medicaid State Settlement
Agreement within 60 days following the Account Establishment Date. (A Medicaid Participating State
shall be deemed to have become a Medicaid Participating State on

-7-

 

the date on which it executed a Medicaid State Settlement Agreement.) If, on the 60th
day following the Account Establishment Date, Eli Lilly is obligated pursuant to the terms of
sub-paragraph III.1.b(ii) to pay to the NY State Account an aggregate amount less than the Medicaid
State Settlement Amount, Eli Lilly shall be entitled to retain any such difference, commingle it
with any other corporate funds, and use it for any purpose, and no State shall be entitled to any
portion of that difference pursuant to the terms of this Agreement. In the event that there are
twenty five (25) or more Medicaid Participating States by the 60th day following the
Account Establishment Date, the deadline for becoming a Medicaid Participating State shall be
extended by 30 days, and Eli Lilly’s rights pursuant to this sub-paragraph III.1.b(iv) shall accrue
on the 90th day following the Account Establishment Date. In the event that the
immediately foregoing clause is triggered, Eli Lilly shall pay the aggregate amount that it owes to
the States that become Medicaid Participating States in the period from 61-90 days following the
Account Establishment Date to the NY State Account, pursuant to written wire instructions provided
by NAMFCU, on the 100th day following the Account Establishment Date or within two (2)
business days following receipt by Eli Lilly of the written wire instructions, whichever is later.

          (c) Subject to the terms of this paragraph, Eli Lilly shall mail checks to affected
Public Health Service entities the aggregate sum of Seven Hundred Fifty One Thousand, Five Hundred
and Forty Three Dollars and Eighty Eight Cents ($751,543.88, plus interest accrued thereon at a
rate of 3% per annum from October 20, 2008, continuing until and including the day before checks are
mailed pursuant to this paragraph (the “Public Health Settlement Amount”). Within 60 days of the
date on which the Court accepts Eli Lilly’s guilty plea in connection with the Federal Criminal
Action and imposes the agreed-upon sentence, Eli

-8-

 

Lilly shall distribute to each affected Public Health Service entity a check in the amount of its
proportionate share of the Public Health Settlement Amount along with a cover letter referencing
this Agreement and providing that, by cashing the check, the entity is releasing Eli Lilly and its
predecessors and current and former parents, affiliates, divisions, subsidiaries, successors,
transferees, heirs, and assigns, and their current and former directors, officers and employees,
individually and collectively, from liability for the Covered Conduct.

          (d) Contingent upon the United States receiving the Federal Settlement Amount
from Eli Lilly, the United States agrees to pay, as soon as feasible after receipt, to Relator
Rudolph
$78,870,877.84 plus the pro rata share of the actual accrued interest paid to the United
States by
Eli Lilly on the amount set forth in Paragraph III.1.a above (“Relator’s Share”).

          (e) Relators have entered into a separate agreement concerning the allocation
of the Relators’ Share among themselves.

     2. Subject to the exceptions in Paragraph 7 below (concerning excluded claims), in
consideration of the obligations of Eli Lilly in this Agreement, conditioned upon Eli Lilly’s full
payment of the Federal Settlement Amount, and subject to Paragraph 16 below (concerning bankruptcy
proceedings commenced within 91 days of the Effective Date of this Agreement or any payment made
under this Agreement), the United States (on behalf of itself, its officers, agents, agencies, and
departments) agrees to release Eli Lilly, its predecessors, current and former parents, affiliates,
divisions, subsidiaries, successors, transferees, heirs, and assigns, and their current and former
directors, officers and employees, individually and collectively, from any civil or administrative
monetary claim the United States has or may have for the Covered Conduct under the False Claims
Act, 31 U.S.C. §§ 3729-3733; the Program Fraud Civil

-9-

 

Remedies Act, 31 U.S.C. §§ 3801-12; any statutory provision creating a cause of action for civil
damages or civil penalties for which the Civil Division of the Department of Justice has actual and
present authority to assert and compromise pursuant to 28 C.F.R. Part O, Subpart I, Section 0.45(D)
(1999) or the common law theories of payment by mistake, unjust enrichment, fraud, disgorgement of
illegal profits, and, if applicable, breach of contract.

     Subject to the exceptions in Paragraph 7 below (concerning excluded claims), in consideration
of the obligations of Eli Lilly in this Agreement, conditioned upon Eli Lilly’s full payment of the
Federal Settlement Amount and compliance with sub-paragraphs III.1.b(i), (ii), and (iv) of this
Agreement, subject to Paragraph 16 below (concerning bankruptcy proceedings commenced within 91
days of the Effective Date of this Agreement or any payment made under this Agreement), the United
States (on behalf of itself, its officers, agents, agencies, and departments) agrees to release Eli
Lilly, its predecessors and current and former parents, affiliates, divisions, subsidiaries,
successors, transferees, heirs, and assigns, and their current and former directors, officers and
employees, individually and collectively, from any claim the United States has or may have for the
Covered Conduct under the Civil Monetary Penalties Law, 42 U.S.C. §1320a-7a.

     3. In consideration of the obligations of Eli Lilly in this Agreement, conditioned upon
Eli Lilly’s full payment of the Federal Settlement Amount and compliance with sub-paragraphs
III.1.b.(i), (ii), and (iv) of this Agreement, Relators Faltaous, Woodward, Vicente, Rudolph,
Rosado, Daywitt, Bradley Lutz, Wetta, and Lofing, for themselves and for their heirs, successors,
transferees, attorneys, agents, and assigns, agree to dismiss with prejudice any currently pending
claims against Eli Lilly and release Eli Lilly, its predecessors and current and

-10-

 

former parents, affiliates, divisions, subsidiaries, successors, transferees, heirs, and assigns,
and their current and former directors, officers, employees, agents, servants, representatives,
attorneys, consultants, successors, heirs, executors, administrators, and assigns, individually and
collectively, from all liability, claims, demands, actions or causes of action whatsoever, known or
unknown, fixed or contingent, in law or in equity, in contract or in tort, under any federal or
state statute or regulation or that they otherwise would have standing to bring, except that they
expressly reserve any claims arising under the qui tam provisions of the False Claims Act of any
State with which Eli Lilly does not execute a Medicaid State Settlement Agreement pursuant to the
terms of this Agreement.

     4. In consideration of the obligations of Eli Lilly set forth in this Agreement and the
Corporate Integrity Agreement (“CIA”) entered into between OIG-HHS and Eli Lilly, conditioned on
Eli Lilly’s payment in full of the Federal Settlement Amount and compliance with sub-paragraphs
III.1.b(i), (ii), and (iv) of this Agreement, and subject to Paragraph 16 below (concerning
bankruptcy proceedings commenced within 91 days of the Effective Date of this Agreement or any
payment under this Agreement), the OIG-HHS agrees to release and refrain from instituting,
directing, or maintaining any administrative action seeking exclusion from the Medicare, Medicaid,
and other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) against Eli Lilly
and Lilly USA, LLC under 42 U.S.C. § 1320a-7a (Civil Monetary Penalties Law) or 42 U.S.C. §
1320a-7(b)(7) (permissive exclusion for fraud, kickbacks or other prohibited activities) for the
Covered Conduct, except as reserved in Paragraph 7 (concerning excluded claims), below, and as
reserved in this Section.

-11-

 

          In consideration of the obligations of Eli Lilly set forth in this Agreement and the CIA
entered into between OIG-HHS and Eli Lilly, conditioned on Eli Lilly’s payment in full of the
Federal Settlement Amount and compliance with sub-paragraphs III.1.b(i), (ii), and (iv) of this
Agreement, and subject to Paragraph 16 below (concerning bankruptcy proceedings commenced within 91
days of the Effective Date of this Agreement or any payment made under this Agreement), the OIG-HHS
agrees to release and refrain from instituting, directing, or maintaining any administrative action
seeking exclusion from Medicare, Medicaid, and other Federal health care programs (as defined in 42
U.S.C. § 1320a-7b(f)) against Eli Lilly under 42 U.S.C. § 1320a-7(b)(l) (permissive exclusion for
conviction relating to fraud) based on the Federal Criminal Action referenced in Paragraph F,
except as reserved in paragraph 7 (concerning excluded claims) below, and as reserved in this
Section.

          The OIG-HHS expressly reserves all rights to comply with any statutory obligations to exclude
Eli Lilly from the Medicare, Medicaid, or other Federal health care programs under 42 U.S.C. §
1320a-7(a) (mandatory exclusion) based upon the Covered Conduct or the Federal Criminal Action.
Nothing in this Section precludes the OIG-HHS from taking action against entities or persons, or
for conduct and practices, for which claims have been reserved in Paragraph 7, below.

     5. In consideration of the obligations of Eli Lilly set forth in this Agreement,
conditioned upon Eli Lilly’s full payment of the Federal Settlement Amount and compliance with
sub-paragraphs III.1.b(i), (ii), and (iv) of this Agreement, and subject to Paragraph 16, below
(concerning bankruptcy proceedings commenced within 91 days of the Effective Date of this Agreement
or any payment under this Agreement), TMA agrees to release and refrain from

-12-

 

instituting, directing, or maintaining any administrative action seeking exclusion from the TRICARE
Program against Eli Lilly, its predecessors and current and former parents, affiliates, divisions,
subsidiaries, successors, transferees, heirs, and assigns, and their current and former directors,
officers and employees, individually and collectively, under 32 C.F.R. § 199.9 for the Covered
Conduct, except as reserved in Paragraph 7 (concerning excluded claims) below, and as reserved in
this Paragraph. TMA expressly reserves its authority to exclude Eli Lilly under 32 C.F.R. §
199.9(f)(1)(i)(A), (f)(1)(i)(B), and (f)(1)(iii), based upon the Covered Conduct. Nothing in this
Paragraph precludes TMA or the TRICARE Program from taking action against entities or persons, or
for conduct and practices, for which claims have been reserved in Paragraph 7, below.

     6. In consideration of the obligations of Eli Lilly set forth in this Agreement and
conditioned upon Eli Lilly’s full payment of the Federal Settlement Amount and compliance with
sub-paragraphs III.1.b(i), (ii), and (iv) of this Agreement, and subject to Paragraph 16 below
(concerning bankruptcy proceedings commenced within 91 days of the Effective Date of this Agreement
or any payment under this Agreement), OPM agrees to release and refrain from instituting,
directing, or maintaining any administrative action against Eli Lilly, its predecessors and current
and former parents, affiliates, divisions, subsidiaries, successors, transferees, heirs, and
assigns, and their current and former directors, officers and employees, individually and
collectively, under 5 U.S.C. § 8902a(b) or 5 C.F.R. Part 919 for the Covered Conduct, except as
reserved in Paragraph 7 (concerning excluded claims) below, and except if required by 5 U.S.C. §
8902a(b). Nothing in this Paragraph precludes OPM from taking action against entities or

-13-

 

persons, or for conduct and practices, for which claims have been reserved in Paragraph 7,
below.

     7. Notwithstanding any term of this Agreement, specifically reserved and excluded
from the scope and terms of this Agreement as to any entity or person (including Eli Lilly and
Relators) are the following claims of the United States:

          (a) Any criminal, civil, or administrative liability arising under Title 26, U.S.
Code (Internal Revenue Code);

          (b) Any criminal liability except as set forth in the Plea Agreement resolving
the Federal Criminal Action;

          (c) Except as explicitly stated in this Agreement, any administrative liability,
including mandatory exclusion from Federal health care programs;

          (d) Any liability to the United States (or its agencies) for any conduct other than the Covered Conduct;

          (e) Any liability based upon such obligations as are created by this
Agreement;

          (f) Any liability for express or implied warranty claims or other claims for
defective or deficient products and services, including quality of goods and services;

          (g) Any liability for personal injury or property damage or for other
consequential damages arising from the Covered Conduct; and

          (h) Any liability for failure to deliver items or services due.

     8. Relators, their heirs, successors, attorneys, agents, and assigns agree not to object to this
Agreement and agree and confirm that this Agreement is fair, adequate, and reasonable

-14-

 

under all the circumstances, pursuant to 31 U.S.C. § 3730(c)(2)(B). Conditioned upon Relator
Rudolph’s receipt of the Relators’ Share, Relators, for themselves individually, and for their
heirs, successors, agents, and assigns, fully and finally release, waive, and forever discharge the
United States, its officers, agents, and employees from any claims arising from or relating to 31
U.S.C. § 3730; from any claims arising from the filing of the Civil Actions identified in
Paragraphs II (B) through II (E); from any other claims for a share of the Settlement Amount; and
in full settlement of any claims Relators may have under this Agreement. This Agreement does not
resolve or in any manner affect any claims the United States has or may have against the Relators
arising under Title 26, U.S. Code (Internal Revenue Code), or any claims arising under this
Agreement.

     9. Eli Lilly waives and shall not assert any defenses it may have to criminal prosecution or
administrative action relating to the Covered Conduct based in whole or in part on a contention
that, under the Double Jeopardy Clause of the Fifth Amendment of the Constitution, or the Excessive
Fines Clause of the Eighth Amendment of the Constitution, this Agreement bars a remedy sought in
such criminal prosecution or administrative action. Nothing in this paragraph or any other
provision of this Agreement constitutes an agreement by the United States concerning the
characterization of the Settlement Amount for purposes of the Internal Revenue laws, Title 26 of
the United States Code.

     10. Eli Lilly fully and finally releases, waives and discharges the United States, its
agencies, employees, servants, and agents from any claims (including attorneys’ fees, costs, and
expenses of every kind and however denominated) that Eli Lilly has asserted, could have asserted,
or may assert in the future against the United States, its agencies, employees, servants,

-15-

 

and agents, related to or arising from the Covered Conduct and the United States’ investigation and
prosecution of the Covered Conduct and the Civil Actions identified in Paragraphs II (B) through
(E).

     11. Neither the Federal Settlement Amount nor the Medicaid State Settlement Amount shall be
decreased as a result of the denial of claims for payment now being withheld from payment by any
State or Federal payer, related to the Covered Conduct; and Eli Lilly shall not resubmit to any
State or Federal payer any previously denied claims, which denials were based on the Covered
Conduct, and shall not appeal or cause the appeal of any such denials of claims.

     12. Eli Lilly agrees to the following:

          (a) Unallowable Costs Defined. All costs (as defined in the Federal Acquisition
Regulation (“FAR”), 48 C.F.R. § 31.205-47 and in Titles XVIII and XIX of the Social Security Act,
42 U.S.C. §§ 1395-1395hhh and 1396-1396v, and the regulations and official program directives
promulgated thereunder) incurred by or on behalf of Eli Lilly, its predecessors, parents,
divisions, subsidiaries, or affiliates, and its present or former officers, directors, employees,
and agents in connection with the following shall be “unallowable costs” on Government contracts:
(1) the matters covered by this Agreement; (2) the United States’ audit and civil and criminal
investigation relating to matters covered by this Agreement; (3) Eli Lilly’s investigation,
defense, and any corrective actions undertaken in response to the United States’ civil and criminal
investigations in connection with the matters covered by this Agreement (including attorneys’
fees); (4) the negotiation and performance of this Agreement and the Medicaid State Settlement
Agreements and any agreement(s) with Relators concerning

-16-

 

fees and costs; (5) the payments made to the United States or any State pursuant to this Agreement
or the Medicaid State Settlement Agreements and any payments that Eli Lilly may make to any qui
tam plaintiffs; and (6) the negotiation of and obligations undertaken pursuant to the CIA to: (a)
retain an independent review organization to perform annual reviews as described in Section III of
the CIA; and (b) prepare and submit reports to OIG-HHS. However, nothing in this Paragraph affects
the status of costs that are not allowable based on any other authority applicable to Eli Lilly.
(All costs described or set forth in this Paragraph are hereafter, “Unallowable Costs”).

          (b) Future Treatment of Unallowable Costs. If applicable, these Unallowable Costs
shall be separately estimated and accounted for by Eli Lilly and Eli Lilly shall not charge such
Unallowable Costs directly or indirectly to any contracts with the United States or any State
Medicaid program, or seek payment for such Unallowable Costs through any cost report, cost
statement, information statement, or payment request submitted by Eli Lilly, its predecessors,
parents, divisions, subsidiaries, or affiliates to any government program.

          (c) Treatment of Unallowable Costs Previously Submitted for Payment. If applicable,
Eli Lilly further agrees that, within 90 days of the Effective Date of this Agreement, it shall
identify to applicable Medicare and TRICARE fiscal intermediaries, carriers, and/or contractors,
and Medicaid, DVA, BOP, and FEHBP fiscal agents, any Unallowable Costs (as defined in this
Paragraph) included in payments previously sought from the United States, or any State Medicaid
Program, including, but not limited to, payments sought in any cost reports, cost statements,
information reports, or payment requests already submitted by Eli Lilly, its predecessors, parents,
divisions, subsidiaries, or affiliates and shall request, and agree, that such

-17-

 

cost reports, cost statements, information reports, or payment requests, even if already settled,
be adjusted to account for the effect of the inclusion of the Unallowable Costs. Eli Lilly agrees
that the United States, at a minimum, shall be entitled to recoup from Eli Lilly any overpayment,
plus applicable interest and penalties, as a result of the inclusion of such Unallowable Costs on
previously-submitted cost reports, information reports, cost statements, or requests for payment.
Any payments due after the adjustments have been made shall be paid to the United States pursuant
to the direction of the Department of Justice and/or of the affected agencies. The United States
reserves its rights to disagree with any calculations submitted by Eli Lilly, its predecessors,
parents, divisions, subsidiaries or affiliates on the effect of inclusion of Unallowable Costs on
Eli Lilly’s or its predecessors’, parents’, divisions’, subsidiaries’ or affiliates’ cost reports,
cost statements, or information reports.

          (d) Nothing in this Agreement shall constitute a waiver of the rights of the United
States to examine or re-examine Eli Lilly’s books and records to determine that no Unallowable
Costs have been claimed in accordance with the provisions of this Paragraph.

     13. This Agreement is intended to be for the benefit of the Parties only. The Parties
do not release any claims against any other person or entity, except to the extent provided
for in Paragraph 14 (Waiver for Beneficiaries paragraph), below.

     14. Eli Lilly shall not seek payment for any of the claims for reimbursement covered
by this Agreement from any health care beneficiaries or their parents, sponsors, legally
responsible individuals, or third party payors based upon the claims defined as Covered
Conduct.

     15. Eli Lilly warrants that it has reviewed its financial situation and that it is currently
solvent within the meaning of 11 U.S.C. §§ 547(b)(3) and
548(a)(1)(B)(ii)(I), and shall remain

-18-

 

solvent following payment of the Federal Settlement Amount and compliance with sub-paragraphs
III.1.b(i), (ii), and (iv) of this Agreement. Further, the Parties expressly warrant that, in
evaluating whether to execute this Agreement, they (a) have intended that the mutual promises,
covenants, and obligations set forth herein constitute a contemporaneous exchange for new value
given to Eli Lilly, within the meaning of 11 U.S.C. § 547(c)(1); and (b) have concluded that these
mutual promises, covenants and obligations do, in fact, constitute such a contemporaneous exchange.
Further, the Parties warrant that the mutual promises, covenants, and obligations set forth herein
are intended to and do, in fact, represent a reasonably equivalent exchange of value that is not
intended to hinder, delay, or defraud any entity that Eli Lilly was or became indebted to on or
after the date of this transfer, within the meaning of 11 U.S.C. § 548(a)(1).

     16. If within 91 days of the Effective Date of this Agreement or of any payment made
under this Agreement, Eli Lilly commences, or a third party commences, any case, proceeding, or
other action under any law relating to bankruptcy, insolvency, reorganization, or relief of debtors
(a) seeking to have any order for relief of Eli Lilly’s debts, or seeking to adjudicate Eli Lilly
as bankrupt or insolvent; or (b) seeking appointment of a receiver, trustee, custodian, or other
similar official for Eli Lilly or for all or any substantial part of Eli Lilly’s assets, Eli Lilly
agrees as follows, to the extent consistent with applicable law:

          (a) Eli Lilly’s obligations under this Agreement may not be avoided pursuant to 11
U.S.C. § 547, and Eli Lilly shall not argue or otherwise take the position in any such case,
proceeding, or action that: (i) Eli Lilly’s obligations under this Agreement may be avoided under
11 U.S.C. § 547; (ii) Eli Lilly was insolvent at the time this Agreement was entered into, or

-19-

 

became insolvent as a result of the payment made to the United States; or (iii) the mutual
promises, covenants, and obligations set forth in this Agreement do not constitute a
contemporaneous exchange for new value given to Eli Lilly.

          (b) In the event that Eli Lilly’s obligations hereunder are avoided for any reason,
including, but not limited to, the exercise of a trustee’s avoidance powers under the Bankruptcy
Code, the United States, at its sole option, may rescind the releases in this Agreement, and bring
any civil and/or administrative claim, action, or proceeding against Eli Lilly for the claims that
would otherwise be covered by the releases provided in this Agreement. If the United States chooses
to do so, Eli Lilly agrees that, for purposes only of any case, action, or proceeding referenced in
the first clause of this Paragraph, (i) any such claims, actions or proceedings brought by the
United States (including any proceedings to exclude Eli Lilly from participation in Medicare,
Medicaid, or other federal health care programs) are not subject to an “automatic stay” pursuant to
11 U.S.C. Section 362(a) as a result of the action, case or proceeding described in the first
clause of this Paragraph, and that Eli Lilly will not argue or otherwise contend that the United
States’ claims, actions or proceedings are subject to an automatic stay; (ii) that Eli Lilly will
not plead, argue or otherwise raise any defenses under the theories of statute of limitations,
laches, estoppel, or similar theories, to any such civil or administrative claims, actions, or
proceedings which are brought by the United States within 30 calendar days of written notification
to Eli Lilly that the releases herein have been rescinded pursuant to this Paragraph, except to the
extent such defenses were available before February 21, 2003; and (iii) the United States and the
Medicaid Participating States have valid claims against Eli Lilly in the aggregate amount of at
least $800,000,000 plus applicable multipliers and

-20-

 

penalties, and they may pursue their claims, inter alia, in the case, action or
proceeding referenced in the first clause of this Paragraph, as well as in any other
case, action, or proceeding; and

          (c) Eli Lilly acknowledges that its agreements in this Paragraph are provided in
exchange for valuable consideration provided in this Agreement.

     17. The United States shall file a Notice of Partial Intervention as to all Federal Counts in
the Civil Actions that pertain to the Covered Conduct, along with an executed copy of this
Agreement. Within five business days after payment of the Federal Settlement Amount and Eli Lilly’s
compliance with sub-paragraph III.1.b(i) of this Agreement, the United States and the Relators
shall file Stipulations of Dismissal With Prejudice as to all Federal Counts in the Civil Actions
that pertain to the Covered Conduct pursuant to the terms of this Agreement.

     18. Except as expressly provided to the contrary in this Agreement, each Party shall bear its
own legal and other costs incurred in connection with this matter, including the preparation and
performance of this Agreement.

     19. Eli Lilly represents that this Agreement is freely and voluntarily entered into
without any degree of duress or compulsion whatsoever.

     20. Relators represent that this Agreement is freely and voluntarily entered into
without any degree of duress or compulsion whatsoever.

     21. This Agreement is governed by the laws of the United States. The Parties agree that the
exclusive jurisdiction and venue for any dispute arising between and among the Parties under this
Agreement shall be the United States District Court for the Eastern District of

-21-

 

Pennsylvania, except that disputes arising under the CIA shall be resolved exclusively through the
dispute resolution provisions set forth in the CIA.

     22. For purposes of construction, this Agreement shall be deemed to have been drafted by all
parties to this Agreement and shall not, therefore, be construed against any Party for that reason
in any subsequent dispute.

     23. This Agreement constitutes the complete agreement between the Parties with respect to the
issues covered by this Agreement. This Agreement may not be amended except by written consent of
the Parties.

     24. The individuals signing this Agreement on behalf of Eli Lilly represent and warrant that
they are authorized by Eli Lilly to execute this Agreement. The individual(s) signing this
Agreement on behalf of Relators represent and warrant that they are authorized by that Relator to
execute this Agreement. The United States signatories represent that they are signing this
Agreement in their official capacities and that they are authorized to execute this Agreement.

     25. This Agreement may be executed in counterparts, each of which constitutes an original and
all of which constitute one and the same Agreement.

     26. This Agreement is binding on Eli Lilly’s successors, transferees, heirs, and
assigns.

     27. This Agreement is binding on Relators’ successors, transferees, heirs, attorneys, agents,
and assigns.

     28. All Parties consent to the United States’ disclosure of this Agreement, and
information about this Agreement, to the public.

-22-

 

     29. This Agreement is effective on the date of signature of the last signatory to the
Agreement (the “Effective Date”). Facsimiles of signatures shall constitute acceptable binding
signatures for purposes of this Agreement.

     30. Notwithstanding any other provision of this Agreement, if the guilty plea referenced in
Paragraph II.F is not accepted by the Court or the Court does not impose the agreed upon sentence
for whatever reason, this Agreement shall be null and void at the option of either the United
States or Eli Lilly. If either the United States or Eli Lilly exercises this option, which option
shall be exercised by notifying all Parties, through counsel, in writing within 5 business days of
the Court’s decision, the Parties will not object and this Agreement will be rescinded. If the
Agreement is rescinded, Eli Lilly waives any affirmative defenses based in whole or in part on the
running of the statute of limitations during the period from the Effective Date of this Agreement
through 30 days after the effective date of the rescission.

-23-

 

[Page intentionally left blank]

-24-

 

UNITED STATES OF AMERICA

	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Laurie Magid
 

LAURIE MAGID
	 	 
	 	Dated: 1/14/09
	 	 
	 

	 	Acting United States Attorney	 	 	 	 	 	 
	 

	 	United States Attorney’s Office	 	 	 	 	 	 
	 

	 	Eastern District of Pennsylvania	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Virginia Gibson
	 	 	 	Dated: 1/14/09	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	VIRGINIA GIBSON	 	 	 	 	 	 
	 

	 	Chief, Civil Division	 	 	 	 	 	 
	 

	 	United States Attorney’s Office	 	 	 	 	 	 
	 

	 	Eastern District of Pennsylvania	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Margaret L. Hutchinson
	 	 	 	Dated: 1/14/09	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	MARGARET L. HUTCHINSON	 	 	 	 	 	 
	 

	 	Deputy Chief, Civil Division	 	 	 	 	 	 
	 

	 	United States Attorney’s Office	 	 	 	 	 	 
	 

	 	Eastern District of Pennsylvania	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Joseph Trautwein
	 	 	 	Dated: 1/14/09	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	JOSEPH TRAUTWEIN	 	 	 	 	 	 
	 

	 	Assistant U.S. Attorney	 	 	 	 	 	 
	 

	 	United States Attorney’s Office	 	 	 	 	 	 
	 

	 	Eastern District of Pennsylvania	 	 	 	 	 	 

-25-

 

	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Patricia Hanower
 

PATRICIA HANOWER
	 	 
	 	Dated: January 14, 2009
	 	 
	 

	 	Trial Attorney	 	 	 	 	 	 
	 

	 	Commercial Litigation Branch	 	 	 	 	 	 
	 

	 	Civil Division	 	 	 	 	 	 
	 

	 	United States Department of Justice	 	 	 	 	 	 

-26-

 

	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Gregory E. Demske
 

GREGORY E. DEMSKE
	 	 
	 	Dated: 1/14/09
	 	 
	 

	 	Assistant Inspector General for Legal Affairs	 	 	 	 	 	 
	 

	 	Office of Counsel to the Inspector General	 	 	 	 	 	 
	 

	 	Office of Inspector General	 	 	 	 	 	 
	 

	 	U.S. Department of Health and Human Services	 	 	 	 	 	 

-27-

 

	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Laurel C. Gillespe
 

LAUREL C. GILLESPE
	 	 
	 	Dated: 12 Jan 2009
	 	 
	 

	 	Deputy General Counsel	 	 	 	 	 	 
	 

	 	TRICARE Management Activity	 	 	 	 	 	 
	 

	 	United States Department of Defense On behalf of the TRICARE program
	 	 	 	 	 	 

Eli Lilly Settlement Agreement

-28-

 

	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Lorraine E. Dettman
 

LORRAINE E. DETTMAN
	 	 
	 	Dated: 1/12/09
	 	 
	 

	 	Assistant Director	 	 	 	 	 	 
	 

	 	for Insurance Services Programs	 	 	 	 	 	 
	 

	 	United States Office of Personnel Management	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ J. David Cope
 

J. DAVID COPE
	 	 
	 	Dated: 1/13/09
	 	 
	 

	 	Assistant Inspector General for Legal Affairs	 	 	 	 	 	 
	 

	 	United States Office of Personnel Management	 	 	 	 	 	 

On behalf of the Federal Employees Health Benefits Program

-29-

 

ELI LILLY AND COMPANY

	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Robert A. Armitage
 

ROBERT A. ARMITAGE
	 	 
	 	Dated: 14 Jan 2009
	 	 
	 

	 	Senior Vice President and General Counsel	 	 	 	 	 	 
	 

	 	Eli Lilly and Company	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Paul E. Kalb
 

PAUL E. KALB, M.D.
	 	 
	 	Dated: 1/14/09	 	 
	 

	 	Sidley Austin LLP	 	 	 	 	 	 
	 

	 	Counsel for Eli Lilly and Company	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Bradford A. Berenson
	 	 	 	Dated: 1/14/09	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	BRADFORD A. BERENSON	 	 	 	 	 	 
	 

	 	Sidley Austin LLP	 	 	 	 	 	 
	 

	 	Counsel for Eli Lilly and Company	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Nina M. Gussack
	 	 	 	Dated: 1/14/09	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	NINA M. GUSSACK	 	 	 	 	 	 
	 

	 	Pepper Hamilton LLP	 	 	 	 	 	 
	 

	 	Counsel for Eli Lilly and Company	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Thomas M. Gallagher
	 	 	 	Dated: 1/14/09	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	THOMAS M. GALLAGHER	 	 	 	 	 	 
	 

	 	Pepper Hamilton LLP	 	 	 	 	 	 
	 

	 	Counsel for Eli Lilly and Company	 	 	 	 	 	 

-30-

 

RELATORS

	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Robert Rudolph
 

ROBERT RUDOLPH
	 	 
	 	Dated: 1/14/09
	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Hector Rosado
	 	 	 	Dated: 1/14/09	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	HECTOR ROSADO	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Robert Evan Daywitt
	 	 	 	Dated: 1/14/09	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	ROBERT EVAN DAYWITT	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Bradley Lutz
	 	 	 	Dated: 1/14/09	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	BRADLEY LUTZ	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ James Wetta
	 	 	 	Dated: 1/14/09	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	JAMES WETTA	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ William Lofing
	 	 	 	Dated: 1/14/09	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	WILLIAM LOFING	 	 	 	 	 	 

-31-

 

	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Michael M. Mustokoff
 

MICHAEL M. MUSTOKOFF
	 	 
	 	Dated: 1/14/09
	 	 
	 

	 	Duane Morris, LLP	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Stephen A. Sheller
	 	 	 	Dated: 1/14/09	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	STEPHEN A. SHELLER	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Gary M. Farmer
	 	 	 	Dated: 1/14/09	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	GARY M. FARMER, JR.	 	 	 	 	 	 
	 

	 	Rothstein Rosenfeldt Adler	 	 	 	 	 	 

     (Attorneys for Robert Rudolph, Hector Rosado, Robert Evan Daywitt, Bradley Lutz, James
Wetta and William Lofing)

-32-

 

	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Joseph Faltaous
	 	 	 	Dated: 1-14-09
	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	JOSEPH FALTAOUS	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Joel Androphy
 

JOEL ANDROPHY
	 	 
	 	Dated: 1-14-09	 	 
	 

	 	SARAH M. FRAZIER	 	 	 	 	 	 
	 

	 	Berg & Androphy	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	(Attorneys for Joseph Faltaous)	 	 	 	 	 	 

-33-

 

	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Steven Woodward
 

STEVEN WOODWARD
	 	 
	 	Dated: 1/13/09
	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Brian P. Kenney
	 	 	 	Dated: 1/14/09	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	BRIAN P. KENNEY	 	 	 	 	 	 
	 

	 	Kenney Egan McCafferty & Young	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	(Attorneys for Steven Woodward)	 	 	 	 	 	 

-34-

 

	 	 	 	 	 	 	 	 	 
	By:
	 	/s/ Jaydeen Vicente
 

JAYDEEN VICENTE	 	 	 	Dated: 01/13/09	 	 
	 
	 	 	 	 	 	 	 	 
	By:
	 	/s/ Brian P. Kenney
 

BRIAN P. KENNEY	 	 	 	Dated: 1/14/09	 	 
	 
	 	Kenney Egan McCafferty & Young	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:
	 	/s/ Mark Burton	 	 	 	Dated: 1/14/09	 	 
	 
	 	 

MARK BURTON	 	 	 	 	 	 
	 
	 	Hersh & Hersh	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	(Attorneys for Jaydeen Vicente)	 	 	 	 	 	 

-35-EX-10.17

 Exhibit 10.17

CORPORATE INTEGRITY AGREEMENT

between the

Office of Inspector General

of the

Department of Health and Human Services

and

Eli Lilly and Company

I.
Preamble

     Eli Lilly and Company (Lilly) hereby enters into this Corporate Integrity Agreement (CIA) with
the Office of Inspector General (OIG) of the United States Department of Health and Human Services
(HHS) to promote compliance with the statutes, regulations, and written directives of Medicare,
Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f))
(Federal health care program requirements) and with the statutes, regulations, and written
directives of the Food and Drug Administration (FDA requirements). Contemporaneously with this CIA,
Lilly is entering into a Settlement Agreement with the United States. Lilly will also enter into
settlement agreements with various States (State Settlement Agreement and Release) and Lilly’s
agreement to this CIA is a condition precedent to those agreements.

     Prior to the Effective Date of this CIA (as defined below), Lilly established a voluntary
compliance program applicable to all Lilly employees (Compliance Program). Lilly’s Compliance
Program includes a Chief Compliance Officer who reports directly to the Board of Directors and the
CEO, and a Compliance Committee. The Compliance Program also includes a Code of Conduct (known as
“The Red Book”) applicable to all employees that is regularly reviewed and disseminated, written
policies and procedures, educational and training initiatives, a Disclosure Program that allows for
the confidential disclosure and investigation of potential compliance violations and appropriate
disciplinary procedures, and regular monitoring and internal auditing procedures.

     Lilly shall continue its Compliance Program throughout the term of this CIA and shall do so in
accordance with the terms set forth below. Lilly may modify its Compliance Program as appropriate,
but, at a minimum, Lilly shall ensure that during the term of this CIA, it shall comply with the
obligations set forth herein.

Corporate Integrity Agreement

Eli Lilly Company

1

 

II.
Term and Scope of the
CIA 

     A. The period of the compliance obligations assumed by Lilly under this CIA
shall be five years from the effective date of this CIA, unless otherwise specified. The
effective date shall be the date by which Lilly is obligated to pay the Federal Settlement
Amount as set forth in the Settlement Agreement between Eli Lilly and the United States
(Effective Date). Each one-year period, beginning with the one-year period following the
first day of the first calendar month following the Effective Date, shall be referred to as a
“Reporting Period.”

     B. Sections VII, IX, X, and XI shall expire no later than 120 days after OIG’s
receipt of: (1) Lilly’s final Annual Report; or (2) any additional materials submitted by
Lilly pursuant to OIG’s request, whichever is later.

     C. The scope of this CIA shall be governed by the following definitions:

	 	1.	 	“Covered Persons” includes:

a. all owners who are natural persons and: (i) have an ownership
interest of 5% or more of the outstanding shares; or (ii) are involved
in the business operations of Lilly or Lilly USA, LLC (Lilly USA);

b. all officers and directors of Lilly and Lilly USA, and all
employees of Lilly and Lilly USA based in the United States except
as carved out below in this Section II.C.1; and

c. all contractors, subcontractors, agents, and other persons who
perform Promotional and Product Services Related Functions (as
defined below in Section II.C.4) on behalf of Lilly or Lilly USA.

Notwithstanding the above, the term “Covered Persons” does not include: (i) officers
or employees of Elanco; (ii) part-time or per diem employees, contractors,
subcontractors, agents, and other persons who are not reasonably expected to work
more than 160 hours per year, except that any such individuals shall become “Covered
Persons” at the point when they work more than 160 hours during the calendar year.

Corporate Integrity Agreement

Eli Lilly Company

2

 

	 	2.	 	“Relevant Covered Persons” includes all Covered Persons whose job
responsibilities relate to Promotional and Product Services Related
Functions. This group includes, but is not limited to, Covered Persons
from the following groups or divisions who perform, supervise, or have
responsibilities relating to, or in support of, the Promotional and Product
Services Related Functions of Lilly or Lilly USA: Financial, Quality,
Information Technology, Legal, Lilly Research Laboratories, Global
Marketing and Sales Organization, Regulatory, Corporate Affairs, and
Human Resources.
	 
	 	3.	 	“Government Reimbursed Products” refers to all Lilly human
pharmaceutical products that are reimbursed by Federal health care
programs. This term includes all products promoted or sold by Lilly or
Lilly USA in the United States.
	 
	 	4.	 	The term “Promotional and Product Services Related Functions”
includes: (a) the selling, detailing, marketing, advertising, promoting, or
branding of Government Reimbursed Products; and (b) the preparation
or dissemination of materials or information about, or the provision of
services relating to, Government Reimbursed Products that are
distributed in the United States.
	 
	 	5.	 	The term “Third Party Educational Activity” shall mean any
continuing
medical education (CME), disease awareness, or other scientific,
educational, or professional program, meeting, or event sponsored by
Lilly, including but not limited to, sponsorship of symposia at medical
conferences.
	 
	 	6.	 	The term “Third Party Personnel” shall mean personnel of the
entities
with whom Lilly or Lilly USA have or may in the future enter into
agreements to co-promote a Government Reimbursed Product in the
United States or engage in joint promotional activities in the United
States relating to such a product. Lilly has represented that: (1) the
Third Party Personnel are employed by entities independent of Lilly or
Lilly USA; (2) Lilly or Lilly USA does not control Third Party
Personnel; and (3) it would be commercially impracticable to compel
the compliance of Third Party Personnel with the requirements set forth
in this CIA. Lilly agrees to promote compliance by Third Party

Corporate Integrity Agreement

Eli Lilly Company

3

 

Personnel with Federal health care program and FDA requirements by complying
with the provisions set forth below in Sections III.B.2, V.A.7, and V.B.4
related to Third Party Personnel who meet the definition of Covered Persons.
Provided that Lilly complies with the requirements of Sections III.B.2, V.A.7,
and V.B.4, Lilly shall not be required to fulfill the other CIA obligations that
would otherwise apply to Third Party Personnel who meet the definition of
Covered Persons.

III. Corporate Integrity Obligations

     Lilly shall establish and maintain a Compliance Program throughout the term of this CIA that
includes the following elements:

     A. Compliance Responsibilities of Certain Lilly Employees and the Board of
Directors.

          1. Chief Compliance Officer. Prior to the Effective Date, Lilly appointed a
Chief Compliance Officer, and Lilly shall maintain a Chief Compliance Officer during
the term of the CIA. The Chief Compliance Officer shall be responsible for developing
and implementing policies, procedures, and practices designed to ensure compliance with
the requirements set forth in this CIA and with Federal health care program requirements
and FDA requirements. The Chief Compliance Officer shall be a member of senior
management of Lilly, shall make periodic (at least quarterly) reports regarding
compliance matters directly to the Board of Directors or a Committee of the Board of
Directors of Lilly, and shall be authorized to report on such matters to the Board of
Directors or such Committee at any time. The Chief Compliance Officer shall not be, or
be subordinate to, the General Counsel or Chief Financial Officer. The Chief Compliance
Officer shall be responsible for monitoring the day-to-day compliance activities engaged
in by Lilly as well as for any reporting obligations created under this CIA.

     Lilly shall report to OIG, in writing, any changes in the identity or position description of
the Chief Compliance Officer, or any actions or changes that would affect the Chief Compliance
Officer’s ability to perform the duties necessary to meet the obligations in this CIA, within 15
days after such a change.

          2. Compliance Committee. Prior to the Effective Date, Lilly established a
Compliance Committee, and Lilly shall maintain a Compliance Committee during the
term of this CIA. The Compliance Committee shall, at a minimum, include the Chief

Corporate Integrity Agreement

Eli Lilly Company

4

 

Compliance Officer and other members of senior management necessary to meet the requirements of
this CIA (e.g., senior executives of relevant departments, such as Legal, Human Resources, Lilly
Research Laboratories, Corporate Affairs, Global Marketing and Sales, Regulatory, Account Based
Markets-Lilly USA, Marketing and Operations — Lilly USA, and Health Care Professional Markets —
Lilly USA). The Chief Compliance Officer shall chair the Compliance Committee and the Compliance
Committee shall support the Chief Compliance Officer in fulfilling his/her responsibilities under
the CIA (e.g., shall assist in the analysis of the organization’s risk areas and shall oversee
monitoring of internal and external audits and investigations).

     Lilly shall report to OIG, in writing, any changes in the composition of the Compliance
Committee, or any actions or changes that would affect the Compliance Committee’s ability to
perform the duties necessary to meet the obligations in this CIA, within 15 days after such a
change.

          3. Board of Directors Compliance Obligations. A Committee of the Board of Directors
(Committee) shall be responsible for the review and oversight of matters related to compliance with
Federal health care program requirements, FDA requirements, and the obligations of this CIA. The
Committee shall, at a minimum, be responsible for the following:

               a. The Committee shall meet at least quarterly to review and
oversee Lilly’s Compliance Program, including but not limited to evaluating its
effectiveness and receiving updates about the activities of the Chief Compliance Officer
and other compliance personnel.

               b. The Committee shall consist of at least three members, all of
whom shall be independent directors. The Chief Compliance Officer is required to make
at least four reports a year to the Committee or more often, if requested by the Committee
or the Chief Compliance Officer.

               c. The Committee shall arrange for the performance of a review
on the effectiveness of Lilly’s Compliance Program (Compliance Program Review) for
each Reporting Period of the CIA and shall review the results of the Compliance Program
Review as part of the review and assessment of Lilly’s Compliance Program. A copy of
the Compliance Program Review Report shall be provided to OIG in each Annual Report
submitted by Lilly.

Corporate Integrity Agreement

Eli Lilly Company

5

 

               d. For each Reporting Period of the CIA, the Committee shall
adopt a resolution, signed by each individual member of the Committee, summarizing its review and
oversight of Lilly’s compliance with Federal health care program requirements, FDA requirements,
and the obligations of this CIA.

     At minimum, the resolution shall include the following language:

     “The [insert name of Committee] Committee of the Board of Directors has made a reasonable
inquiry into the operations of Lilly’s Compliance Program, including but not limited to evaluating
its effectiveness and receiving updates about the activities of its Chief Compliance Officer and
other compliance personnel. The Board also has arranged for the performance of, and reviewed the
result of, the Compliance Program Review. Based on its inquiry, the Committee has concluded that,
to the best of its knowledge, Lilly has implemented an effective Compliance Program to meet Federal
health care program requirements, FDA requirements, and the obligations of the CIA.”

     If the Committee is unable to provide such a conclusion in the resolution, the Committee shall
include in the resolution a written explanation of the reasons why it is unable to provide the
conclusion and the steps it is taking to assure implementation by Lilly of an effective Compliance
Program at Lilly.

     Lilly shall report to OIG, in writing, any changes in the composition of the Committee, or any
actions or changes that would affect the Committee’s ability to perform the duties necessary to
meet the obligations in this CIA, within 15 days after such a change.

     The Board of Directors may by resolution reserve to itself the powers and responsibilities
assigned to the Committee under this CIA. In that event, all references in this CIA to the
Committee shall be deemed to be references to the Board of Directors.

          4. Management Accountability and Certifications: In addition to the responsibilities set
forth in this CIA for all Covered Persons, certain Lilly employees (“Certifying Employees”) are
specifically expected to monitor and oversee activities within their areas of authority and shall
annually certify, in writing or electronically, that the applicable Lilly component is compliant
with Federal health care program requirements, FDA requirements, and the obligations of this CIA.
These Certifying Employees shall include, at a minimum, the following individuals from Lilly:
President and Chief Executive Officer; and Executive Vice President, Global Marketing and Sales.

Corporate Integrity Agreement

Eli Lilly Company

6

 

They also shall include, at minimum, the following individuals from Lilly USA: President, U.S.
Operations; Senior Vice President, Account-Based Markets; Senior Vice President, Health Care
Professional Markets; Vice President, Chief Marketing and Operations Officer; and all national and
executive sales directors, brand leaders, and business unit leaders in the HCP Markets, executive
directors and directors in Account-Based Markets, and executive directors and directors in
Marketing and Operations.

     For each Reporting Period, each Certifying Employee shall sign a certification that states:

     “I have been trained on and understand the compliance requirements and responsibilities
as they relate to [department or functional area], an area under my supervision. My job
responsibilities include ensuring compliance with regard to the
                    
[insert name of the department or functional area.] To the best of my knowledge,
except as otherwise described herein, the                     
[insert name of department or functional
area] of Lilly is in compliance with all applicable Federal health care program
requirements, FDA requirements, and the obligations of the CIA.”

     B. Written Standards.

          1. Code of Conduct. Prior to the Effective Date, Lilly developed, implemented, and distributed
a written Code of Conduct (known as “The Red Book”) to all Covered Persons. Lilly currently
requires all newly employed Covered Persons to certify in writing or electronically, that they have
received, read, understood, and shall abide by Lilly’s Code of Conduct. Lilly shall continue to
make the promotion of, and adherence to, the Code of Conduct an element in evaluating the
performance of all Covered Persons.

          The Code of Conduct sets forth and shall continue to set forth, at a minimum, the
following:

a. Lilly’s commitment to full compliance with all Federal health care
program and FDA requirements, including its commitment to market, sell,
promote, research, develop, provide information about, and advertise its
products in accordance with Federal health program requirements and FDA
requirements;

Corporate Integrity Agreement

Eli Lilly Company

7

 

b. Lilly’s requirement that all of its Covered Persons shall be
expected to comply with all Federal health care program and FDA
requirements and with Lilly’s own Policies and Procedures as
implemented pursuant to Section III.B (including the requirements of
this CIA);

c. the requirement that all of Lilly’s Covered Persons shall be
expected to report to the Chief Compliance Officer, or other
appropriate individual designated by Lilly, suspected violations of
any Federal health care program and FDA requirements or of Lilly’s
own Policies and Procedures;

d. the possible consequences to both Lilly and Covered Persons of
failure to comply with Federal health care program and FDA
requirements and with Lilly’s own Policies and Procedures and the
failure to report such noncompliance; and

e. the right of all individuals to use the Disclosure Program described
in Section III.E, and Lilly’s commitment to nonretaliation and to
maintain, as appropriate, confidentiality and anonymity with respect
to such disclosures.

     To the extent not already accomplished, within 120 days after the Effective Date, the Code of
Conduct shall be distributed to each Covered Person and each Covered Person shall certify, in
writing or electronically, that he or she has received, read, understood, and shall abide by
Lilly’s Code of Conduct. New Covered Persons shall receive the Code of Conduct and shall complete
the required certification within 30 days after becoming a Covered Person or within 120 days after
the Effective Date, whichever is later.

     Lilly shall periodically review the Code of Conduct to determine if revisions are
appropriate and shall make any necessary revisions based on such review. Any revised Code of
Conduct shall be distributed within 30 days after any revisions are finalized by the Compliance
Office. Each Covered Person shall certify, in writing or electronically, that he or she has
received, read, understood, and shall abide by the revised Code of Conduct within 30 days after
the distribution of the revised Code of Conduct.

Corporate Integrity Agreement

Eli Lilly Company

8

 

          2. Third Party Personnel. Within 90 days after the Effective Date, and
annually thereafter by the anniversary of the Effective Date, Lilly shall send a letter to
each entity employing Third Party Personnel. The letter shall outline Lilly’s obligations
under the CIA and its commitment to full compliance with all Federal health care
program and FDA requirements. The letter shall include a description of Lilly’s
Compliance Program. Lilly shall attach a copy of its Code of Conduct to the letter and
shall request the entity employing Third Party Personnel to either: (a) make a copy of
Lilly’s Code of Conduct and a description of Lilly’s Compliance Program available to its
Third Party Personnel; or (b) represent to Lilly that it has and enforces a substantially
comparable code of conduct and compliance program for its Third Party Personnel.

          3. Policies and Procedures. Prior to the Effective Date, Lilly implemented
written Policies and Procedures regarding the operation of the Compliance Program and
Lilly’s compliance with Federal health care program and FDA requirements (Policies and
Procedures). To the extent not already accomplished, within 90 days after the Effective
Date, Lilly shall ensure that the Policies and Procedures address or shall continue to
address:

	 	a.	 	the subjects relating to the Code of Conduct
identified in Section
III.B.1;
	 
	 	b.	 	appropriate ways to conduct Promotional and
Product Services
Related Functions in compliance with all applicable Federal
healthcare program requirements, including, but not limited to the
Federal anti-kickback statute (codified at 42 U.S.C. § 1320a-7b),
and the False Claims Act (codified at 31 U.S.C. §§ 3729-3733);
	 
	 	c.	 	appropriate ways to conduct Promotional and
Product Services
Related Functions in compliance with all applicable FDA

requirements;
	 
	 	d.	 	the materials and information that may be
distributed by Lilly
sales representatives and account executives about Lilly’s
Government Reimbursed Products and the manner in which Lilly
sales representatives and account executives respond to requests
for information about non-FDA approved (or “off-label”) uses of
Lilly’s Government Reimbursed Products;

Corporate Integrity Agreement

Eli Lilly Company

9

 

	 	e.	 	the materials and information that may be distributed by the Lilly
Answers Center (TLAC) and the mechanisms through, and
manner in which, TLAC receives and responds to requests for
information submitted by sales representatives and account
executives about non-FDA approved (“off-label”) uses of Lilly’s
Government Reimbursed Products; the form and content of
information disseminated by Lilly in response to such requests;
and the internal review process for the information disseminated.
	 
	 	 	 	The Policies and Procedures shall include a requirement that TLAC develop
database(s) to track requests for information about Lilly’s products that
are submitted by Lilly’s sales representatives and account executives, or
by members of the public, to TLAC. This database shall be referred to as
the “TLAC Database.” The TLAC Database shall include the following items
of information for each unique inquiry (Inquiry) received for information
about Lilly’s products: 1) date of Inquiry; 2) form of Inquiry (e.g.,
fax, phone, etc.); 3) name of the requesting health care professional
(HCP) or health care institution (HCI) in accordance with applicable
privacy laws; 4) nature and topic of request (including exact language of
the Inquiry if made in writing); 5) nature/form of the response from
Lilly (including a record of the materials provided to the HCP or HCI in
response to the request); and 6) the name of the Lilly representative who
called on or interacted with the HCP or HCI, if known;
	 
	 	f.	 	systems, processes, policies, and procedures
relating to the
manner and circumstances under which Medical Liaisons and
Outcomes Liaisons participate in meetings or events with HCPs
or HCIs (either alone or with sales representatives or account
executives) and the role of the Medical Liaisons and Outcomes
Liaisons at such meetings or events, as well as how they handle
responses to unsolicited requests about off-label indications of
Lilly’s Government Reimbursed Products;
	 
	 	g.	 	systems, processes, policies, and procedures
relating to the
development, implementation, and review of call plans using

Corporate Integrity Agreement

Eli Lilly Company

10

 

Lilly’s Territory to Physician (TTP) business rules for field sales
representatives who promote Government Reimbursed Products. For each
Government Reimbursed Product, the Policies and Procedures shall require
that Lilly review the call plans for the product and the bases upon, and
circumstances under, which HCPs and HCIs belonging to specified medical
specialties or types of clinical practice are included in, or excluded
from, the call plans. The Policies and Procedures shall also require that
Lilly modify the call plans as necessary to ensure that Lilly is
promoting its Government Reimbursed Products in a manner that complies
with all applicable Federal health care program and FDA requirements. The
call plan reviews shall occur at least annually and shall also occur each
time when the FDA approves a new or additional indication for a
Government Reimbursed Product;

	 	h.	 	systems, processes, policies, and procedures
relating to the development, implementation, and review of plans for the
distribution of samples of Lilly’s Government Reimbursed Products
(Sample Distribution Plans). This shall include a review of the bases
upon, and circumstances under, which HCPs and HCIs belonging to
specified medical specialties or types of clinical practice may receive
samples from Lilly (including, separately, from Lilly sales
representatives or account executives and/or directly from Lilly’s
medical services department). The Policies and Procedures shall also
require that Lilly modify the Sample Distribution Plans as necessary to
ensure that Lilly is promoting its products in a manner that complies
with all applicable Federal health care program and FDA requirements;
	 
	 	i.	 	consultant or other fee-for-service arrangements entered into with
HCPs or HCIs (including, but not limited to speaker programs,
speaker training programs, presentations, consultant task force
meetings, advisory boards, and ad hoc advisory activities, and any other
financial engagement or arrangement with an HCP or HCI,) and all events
and expenses relating to such engagements or arrangements. These
Policies and Procedures shall be designed to ensure that the
arrangements and related events are

Corporate Integrity Agreement

Eli Lilly Company

11

 

used for legitimate and lawful purposes in accordance with applicable
Federal health care program and FDA requirements. The Policies shall
include requirements about the content and circumstances of such
arrangements and events;

	 	j.	 	programs to educate field representatives,
including but not limited to presentations by HCPs at sales meetings and
experience-based learning activities. These Policies and Procedures
shall be designed to ensure that the programs are used for legitimate
and lawful purposes in accordance with applicable Federal health care
program and FDA requirements. The Policies shall include requirements
about the content and circumstances of such arrangements and events;
	 
	 	k.	 	sponsorship or funding of grants (including
educational grants) or charitable contributions. These Policies and
Procedures shall be designed to ensure that Lilly’s funding and/or
sponsorship complies with all applicable Federal health care program and
FDA requirements;
	 
	 	l.	 	funding of, or participation in, any Third
Party Educational Activity as defined in Section II.C.5 above. These
Policies and Procedures shall be designed to ensure that Lilly’s
funding and/or sponsorship of such programs satisfies all applicable
Federal health care program and FDA requirements.

The Policies and Procedures shall require that: 1) Lilly disclose its
financial support of the Third Party Educational Activity and, to the
extent feasible consistent with subsection 5 below, any financial
relationships with faculty, speakers, or organizers at such Activity; 2)
as a condition of funding, the third party shall agree to disclose
Lilly’s financial support of the Third Party Educational Activity and any
financial relationships that Lilly might have with faculty, speakers, or
organizers at such Activity; 3) any faculty, speakers, or organizers at
the Third Party Educational Activity disclose any financial relationship
with Lilly; 4) the Third Party Educational Activity have an educational
focus; 5) the content, organization, and operation of the Third

Corporate Integrity Agreement

Eli Lilly Company

12

 

Party Educational Activity be independent of Lilly control; 6) Lilly
support only Third Party Educational Activity that is non-promotional in
tone/nature; and 7) Lilly support of a Third Party Educational Activity
shall be contingent on the provider’s commitment to provide information
at the Educational Activity that is fair, balanced, accurate and not
misleading;

	 	m.	 	review of all promotional and written materials
and information intended to be disseminated outside Lilly by appropriate
qualified personnel (such as regulatory, medical, and/or legal
personnel) in a manner designed to ensure that legal, regulatory, and
medical concerns are properly addressed during Lilly’s review and
approval process and are elevated when appropriate. The Policies and
Procedures shall be designed to ensure that such materials and
information, when finally approved, comply with all applicable Federal
health care program and FDA requirements;
	 
	 	n.	 	sponsorship or funding of research or related
activities. These Policies and Procedures shall be designed to ensure
that Lilly’s funding and/or sponsorship complies with all applicable
Federal health care program and FDA requirements;
	 
	 	o.	 	 compensation (including salaries and bonuses)
for Relevant Covered Persons. These Policies and Procedures shall be
designed to ensure that financial incentives do not inappropriately
motivate such individuals to engage in improper promotion, sales, and
marketing of Lilly’s products; and
	 
	 	p.	 	disciplinary policies and procedures for
violations of Lilly’s Policies and Procedures, including policies
relating to Federal
health care program and FDA requirements.

     To the extent not already accomplished, within 120 days after the Effective Date, the relevant
portions of the Policies and Procedures shall be made available to all Covered Persons whose job
functions relate to those Policies and Procedures. Appropriate and knowledgeable staff shall be
available to explain the Policies and Procedures.

Corporate Integrity Agreement

Eli Lilly Company

13

 

          At least annually (and more frequently, if appropriate), Lilly shall assess and update, as
necessary, the Policies and Procedures. Within 30 days after the effective date of any revisions,
the relevant portions of any such revised Policies and Procedures shall be made available to all
Covered Persons whose job functions relate to those Policies and Procedures.

     C. Training and Education.

     Lilly represents that it provides training to its employees on a regular basis concerning a
variety of topics. The training covered by this CIA need not be separate and distinct from the
regular training provided by Lilly, but instead may be integrated fully into such regular training
so long as the training covers the areas specified below.

               1. General Training. Within 120 days after the Effective Date, Lilly shall provide at least
two hours of General Training to each Covered Person. This training, at a minimum, shall explain
Lilly’s:

a. CIA requirements; and

b. Lilly’s Compliance Program (including the Code of Conduct and
the Policies and Procedures as they pertain to general compliance
issues).

          To the extent that Lilly provided General Training to Covered Persons during the 180 days
immediately prior to the Effective Date that satisfied the requirements set forth in Section
III.C.1.b above, the OIG shall credit that training for purposes of satisfying Lilly’s General
Training obligations of this Section III.C.1 for the first Reporting Period. Lilly may satisfy its
remaining General Training obligations for the Covered Persons who received the training described
in the preceding sentence by notifying them within 90 days after the Effective Date in writing or
in electronic format of the fact that Lilly entered a CIA and providing an explanation of Lilly’s
requirements and obligations under
the CIA.

          New Covered Persons shall receive the General Training described above within 30 days after
becoming a Covered Person or within 120 days after the Effective Date, whichever is later. After
receiving the initial General Training described above, each Covered Person shall receive at least
one hour of General Training in each subsequent Reporting Period.

Corporate Integrity Agreement

Eli Lilly Company

14

 

          2. Specific Training. Within 120 days after the Effective Date, each Relevant Covered Person
shall receive at least three hours of Specific Training applicable to their specific job functions
in addition to the General Training required above.

          This Specific Training shall include a discussion of:

	 	a.	 	all applicable Federal health care program
requirements relating
to Promotional and Product Services Related Functions;
	 
	 	b.	 	all applicable FDA requirements relating
to Promotional and
Product Services Related Functions;
	 
	 	c.	 	all Lilly Policies and Procedures
and other requirements
applicable to Promotional and Product Services Related

Functions;
	 
	 	d.	 	the personal obligation of each individual
involved in
Promotional and Product Services Related Functions to comply
with all applicable Federal health care program and FDA
requirements and all other applicable legal requirements;
	 
	 	e.	 	the legal sanctions for violations of the
applicable Federal health
care program and FDA requirements; and
	 
	 	f.	 	examples of proper and improper practices
related to Promotional
and Product Services Related Functions.

     To the extent that Lilly provided Specific Training to Relevant Covered Persons during the 180
days immediately prior to the Effective Date that satisfied the requirements set forth in this
Section III.C.2 above, the OIG shall credit that training for purposes of satisfying Lilly’s
Specific Training obligations of this Section III.C.2 for the first Reporting Period.

     New Relevant Covered Persons shall receive this training within 30 days after the beginning of
their employment or becoming Relevant Covered Persons, or within 120 days after the Effective Date,
whichever is later. A Lilly employee who has completed the Specific Training shall review or
supervise (as applicable) a new Relevant Covered

Corporate Integrity Agreement

Eli Lilly Company

15

 

Person’s work, to the extent that the work relates to Promotional and Product Services Related
Functions, until such time as the new Relevant Covered Person completes his or her Specific
Training.

     After receiving the initial Specific Training described in this Section, each Relevant Covered
Person shall receive at least three hours of Specific Training in each subsequent Reporting Period.

          3. Certification. Each individual who is required to complete training shall
certify, in writing or electronically, if applicable, that he or she has received the required
training. The certification shall specify the type of training received and the date
received. The Chief Compliance Officer (or designee) shall retain the certifications,
along with all course materials. These shall be made available to OIG, upon request.

          4. Qualifications of Trainer. Persons providing the training shall be
knowledgeable about the subject area of the training, including applicable Federal health
care program and FDA requirements. The training and education required under this
Section III.C may be provided by supervisory employees, knowledgeable staff, Lilly
trainers, and/or outside consultant trainers selected by Lilly, or may be satisfied by
relevant continuing education programs provided they cover the topics outlined above in
Section III.C.2.

          5. Update of Training. Lilly shall review the training annually, and, where
appropriate, update the training to reflect changes in Federal health care program
requirements, FDA requirements, any issues discovered during any internal audits or any
IRO Review, and any other relevant information.

          6. Computer-based Training. Lilly may provide the training required
under this CIA through appropriate computer-based training approaches. If Lilly chooses
to provide computer-based training, it shall make available appropriately qualified and
knowledgeable staff or trainers to answer questions or provide additional information to
the Covered Persons receiving such training. In addition, if Lilly chooses to provide
computer-based General or Specific Training, all applicable requirements to provide a
number of “hours” of training in this Section III.C may be met with respect to computer-based training by providing the required number of “normative” hours as that term is used
in the computer-based training industry.

Corporate Integrity Agreement

Eli Lilly Company

16

 

D. Review Procedures.

          1. General Description.

a. Engagement of Independent Review Organization. Within 90 days
after the Effective Date, Lilly shall engage an entity (or entities),
such as an accounting, auditing, or consulting firm (hereinafter
“Independent Review Organization” or “IRO”), to perform reviews
to assist Lilly in assessing and evaluating its Promotional and
Product Services Related Functions. The applicable requirements
relating to the IRO are outlined in Appendix A to this CIA, which is
incorporated by reference.

Each IRO engaged by Lilly shall have expertise in applicable Federal health
care program and FDA requirements as may be appropriate to the Review for
which the IRO is retained. Each IRO shall assess, along with Lilly, whether
it can perform the engagement in a professionally independent and objective
fashion, as appropriate to the nature of the review, taking into account any
other business relationships or other engagements that may exist.

The IRO(s) shall conduct reviews that assess Lilly’s systems, processes,
policies, procedures, and practices relating to Promotional and Product
Services Related Functions (Promotional and Product Services Reviews).

b. Frequency and Brief Description of Reviews. As set forth more
fully in Appendix B, the Promotional and Product Services Review
shall consist of two components — a Systems Review and a
Transactions Review. The Systems Review shall assess Lilly’s
systems, processes, policies, and procedures relating to Promotional
and Product Services Related Functions. If there are no material
changes in Lilly’s systems, processes, policies, and procedures
relating to Promotional and Product Services Related Functions, the
Promotional and Product Services Systems Review shall be performed for the
periods covering the first and fourth Reporting Periods. If Lilly materially
changes its systems, processes, policies, and procedures relating to
Promotional and Product Services Related Functions, the IRO shall perform a
Systems Review for the

Corporate Integrity Agreement

Eli Lilly Company

17

 

Reporting Period in which such changes were made in addition to
conducting the Systems Review for the first and fourth Reporting Periods.

The Promotional and Product Services Transactions Review shall be performed
annually and shall cover each of the five Reporting Periods. The IRO(s) shall
perform all components of each annual Transaction Review. As set forth more
fully in Appendix B, the Transactions Review shall include several
components, including a review relating to inquiries included in Lilly’s TLAC
Database, a review of Lilly’s Call Plan Assessments, a review of Sampling
Events, and a review of records relating to a sample of the Payments that are
reported by Lilly pursuant to Section III.M below. In addition, each
Transactions Review shall also include a review of up to three additional
areas or practices of Lilly identified by the OIG in its discretion
(hereafter “Additional Items”.)

For purposes of identifying the Additional Items to be included in the
Transactions Review for a particular Reporting Period, the OIG will consult
with Lilly and may consider internal audit work conducted by Lilly and/or
the Lilly Compliance Monitoring Program, Lilly’s Government Reimbursed
Product portfolio, the nature and scope of Lilly’s promotional practices and
arrangements with HCPs and HCIs, and other information known to it.

As set forth more fully in Section III.E of Appendix B, Lilly may propose to
the OIG that its internal audit(s) be partially substituted for one or more
of the Additional Items that would otherwise be reviewed by the IRO as part
of the Transactions Review. The OIG retains sole discretion over whether,
and in what manner, to allow Lilly’s internal audit work to be substituted
for a portion of the
Additional Items review conducted by the IRO.

The OIG shall notify Lilly of the nature and scope of the IRO review for
each of the Additional Items not later than 120 days prior to the end of
each Reporting Period. Prior to undertaking the review of the Additional
Items, the IRO and/or Lilly shall submit an audit work

Corporate Integrity Agreement

Eli Lilly Company

18

 

plan to the OIG for approval and the IRO shall conduct the review of the
Additional Items based on a work plan approved by the OIG.

c. Retention of Records. The IRO and Lilly shall retain and make available to
OIG, upon request, all work papers, supporting documentation, correspondence,
and draft reports (those exchanged between the IRO and Lilly) related to the
reviews.

          2. IRO Review Reports. The IRO(s) shall prepare a report (or reports)
based upon each Review performed. The information and content to be included in the
report is described in Appendix B, which is incorporated by reference.

          3. Validation Review. In the event OIG has reason to believe that: (a) any
IRO Review fails to conform to the requirements of this CIA; or (b) the IRO’s findings or
Review results are inaccurate, OIG may, at its sole discretion, conduct its own review to
determine whether the applicable IRO Review complied with the requirements of the CIA
and/or the findings or Review results are inaccurate (Validation Review). Lilly shall pay
for the reasonable cost of any such review performed by OIG or any of its designated
agents. Any Validation Review of Reports submitted as part of Lilly’s final Annual
Report shall be initiated no later than one year after Lilly’s final submission (as described
in Section II) is received by OIG.

          Prior to initiating a Validation Review, OIG shall notify Lilly of its intent to do so and
provide a written explanation of why OIG believes such a review is necessary. To resolve any
concerns raised by OIG, Lilly may request a meeting with OIG to: (a) discuss the results of any
Review submissions or findings; (b) present any additional information to clarify the results of
the applicable Review or to correct the inaccuracy of the Review; and/or (c) propose alternatives
to the proposed Validation Review. Lilly agrees to provide any additional information as may be
requested by OIG under this Section III.D.3 in an expedited manner. OIG will attempt in good faith
to resolve any Review issues with Lilly prior to conducting a Validation Review. However, the final
determination as to whether or not to proceed with a Validation Review shall be made at the sole
discretion of OIG.

          4. Independence and Objectivity Certification. The IRO shall include in its
report(s) to Lilly a certification or sworn affidavit that it has evaluated its professional
independence and objectivity, as appropriate to the nature of the engagement, with regard

Corporate Integrity Agreement

Eli Lilly Company

19

 

to the applicable Review and that it has concluded that it is, in fact, independent and
objective.

     E. Disclosure Program.

     Lilly represents that it has a disclosure program designed to facilitate communications
relating to compliance with Federal health care program and FDA requirements and Lilly’s policies
(the “Disclosure Program”). During the term of the CIA, Lilly shall maintain a Disclosure Program
that includes a mechanism (a toll-free compliance telephone line and/ or on-line electronic
reporting) to enable individuals to disclose, to the Chief Compliance Officer or some other person
who is not in the disclosing individual’s chain of command, any identified issues or questions
associated with Lilly’s policies, conduct, practices, or procedures with respect to a Federal
health care program or FDA requirement believed by the individual to be a potential violation of
criminal, civil, or administrative law. Lilly shall continue to appropriately publicize the
existence of the disclosure mechanism (e.g., via periodic e-mails to employees or by posting the
information in prominent common areas).

     The Disclosure Program shall emphasize a nonretaliation policy, and shall include a reporting
mechanism for anonymous communications for which appropriate confidentiality shall be maintained.
Disclosures made by individuals residing outside the United States shall be in accordance with
applicable laws, including the European Union Data Protection Directive. Upon receipt of a
disclosure, the Chief Compliance Officer (or designee) shall gather all relevant information from
the disclosing individual. The Chief Compliance Officer (or designee) shall make a preliminary,
good faith inquiry into the allegations set forth in every disclosure to ensure that he or she has
obtained all of the information necessary to determine whether a further review should be
conducted. For any disclosure that is sufficiently specific so that it reasonably: (1) permits a
determination of the appropriateness of the alleged improper practice; and (2) provides an
opportunity for taking corrective action, Lilly shall conduct an internal review of the allegations
set forth in the disclosure and ensure that proper follow-up is conducted.

     The Chief Compliance Officer (or designee) shall maintain a disclosure log, which shall
include a record and summary of each disclosure received (whether anonymous or not), the status of
the respective internal reviews, and any corrective action taken in response to the internal
reviews. The disclosure log shall be made available to OIG upon request.

Corporate Integrity Agreement

Eli Lilly Company

20

 

     F. Ineligible Persons.

          1. Definitions. For purposes of this CIA:

          a. an “Ineligible Person” shall include an individual or entity who:

i. is currently excluded, debarred, suspended, or otherwise
ineligible to participate in the Federal health care programs or in
Federal procurement or nonprocurement programs; or

ii. has been convicted of a criminal offense that falls within the
ambit of 42 U.S.C. § 1320a-7(a), but has not yet been excluded,
debarred, suspended, or otherwise declared ineligible.

          b. “Exclusion Lists” include:

i. the HHS/OIG List of Excluded Individuals/Entities (available
through the Internet at http://www.oig.hhs.gov); and

ii. the General Services Administration’s List of Parties
Excluded from Federal Programs (available through the
Internet at http://www. epls. gov).

          c. “Screened Persons” shall include all Covered Persons.

          2. Screening Requirements. Lilly shall ensure that all Screened Persons are
not Ineligible Persons, by implementing the following screening requirements.

a. Lilly shall screen all Screened Persons against the Exclusion Lists
 prior to engaging their services and, as part of the hiring or contracting process, shall require such Screened Persons to disclose whether
they are Ineligible Persons.

Corporate Integrity Agreement

Eli Lilly Company

21

 

b. Lilly shall screen all Screened Persons against the Exclusion Lists
within 90 days after the Effective Date and on an annual basis
thereafter.

c. Lilly shall implement a policy requiring all Screened Persons to
disclose immediately any debarment, exclusion, suspension, or other
event that makes that person an Ineligible Person.

          Nothing in this Section affects the responsibility of (or liability for) Lilly to (if
applicable) refrain from billing Federal health care programs for items or services furnished,
ordered, or prescribed by an Ineligible Person. Lilly understands that items or services furnished
by excluded persons are not payable by Federal health care programs and that Lilly may be liable
for overpayments (if applicable) and/or criminal, civil, and administrative sanctions for employing
or contracting with an excluded person regardless of whether Lilly meets the requirements of
Section III.F.

          3. Removal Requirement. If Lilly has actual notice that a Screened Person
has become an Ineligible Person, Lilly shall remove such Screened Person from
responsibility for, or involvement with, Lilly’s business operations related to the Federal
health care programs and shall remove such Screened Person from any position for which
the Screened Person’s compensation or the items or services furnished, ordered, or
prescribed by the Screened Person are paid in whole or part, directly or indirectly, by
Federal health care programs or otherwise with Federal funds at least until such time as
the Screened Person is reinstated into participation in the Federal health care programs.

          4. Pending Charges and Proposed Exclusions. If Lilly has actual notice
that a Screened Person is charged with a criminal offense that falls within the ambit of 42
U.S.C. §§ 1320a-7(a), 1320a-7(b)(1)-(3), or is proposed for exclusion during the Screened
Person’s employment or contract term, Lilly shall take all appropriate actions to ensure
that the responsibilities of that Screened Person have not and shall not adversely affect the
accuracy of any claims submitted to any Federal health care program.

     G. Notification
of Government Investigation or Legal Proceedings.

Within 30 days after discovery by senior management at U.S. corporate headquarters of Lilly or
Lilly USA, Lilly shall notify OIG, in writing, of any ongoing investigation or legal proceeding
known to Lilly conducted or brought by a governmental entity or its agents involving an allegation
that Lilly has committed a crime or has engaged in

Corporate Integrity Agreement

Eli Lilly Company

22

 

fraudulent activities. This notification shall include a description of the allegation, the
identity of the investigating or prosecuting agency, and the status of such investigation or legal
proceeding. Lilly shall also provide written notice to OIG within 30 days after the resolution of
the matter, and shall provide OIG with a description of the findings and/or results of the
investigation or proceedings, if any.

     H. Reporting.

          1. Reportable Events.

a. Definition of Reportable Event. For purposes of this CIA, a
“Reportable Event” means anything that involves:

i. a matter that a reasonable person would consider a probable
violation of criminal, civil, or administrative laws applicable to
any Federal health care program and/or applicable to any FDA
requirements relating to the promotion of Lilly Government
Reimbursed Products for which penalties or exclusion may be
authorized; or

ii. the filing of a bankruptcy petition by Lilly.

A Reportable Event may be the result of an isolated event or a series of
occurrences.

b. Reporting of Reportable Events. If Lilly or Lilly USA determines
(after a reasonable opportunity to conduct an appropriate review or
investigation of the allegations) through any means that there is a
Reportable Event, Lilly shall notify OIG, in writing, within 30 days
after making the determination that the Reportable Event exists. The
report to OIG shall include the following information:

i. a complete description of the Reportable Event, including the relevant facts, persons involved, and legal and Federal health
care program and/or FDA authorities implicated;

ii. a description of Lilly’s actions taken to correct the
Reportable Event; and

Corporate Integrity Agreement

Eli Lilly Company

23

 

iii. any further steps Lilly plans to take to address the
Reportable Event and prevent it from recurring.

iv. If the Reportable Event involves the filing of a bankruptcy
petition, the report to the OIG shall include documentation of the
filing and a description of any Federal health care program
authorities and/or FDA authorities implicated.

v. Lilly shall not be required to report as a Reportable Event any
matter previously disclosed under Section III.G.

     I. Notification of Communications with FDA.

     Within 30 days after the date of any written report, correspondence, or communication between
Lilly and the FDA that materially discusses Lilly’s or a Covered Person’s actual or potential
unlawful or improper promotion of Lilly’s products (including any improper dissemination of
information about off-label indications), Lilly shall provide a copy of the report, correspondence,
or communication to the OIG. Lilly shall also provide written notice to the OIG within 30 days
after the resolution of any such disclosed off-label matter, and shall provide the OIG with a
description of the findings and/or results of the matter, if any.

     J. Review of Records Reflecting the Content of Detailing Sessions.

     For each Reporting Period, Lilly shall obtain non-Lilly records (e.g., Verbatims, message
recall studies, or similar records) generated by an independent entity (Survey Entity) reflecting
the purported content and subject matter of detailing interactions between Lilly sales
representatives and HCPs for up to three Covered Products (as defined below). In order to satisfy
its obligations under this Section III.J, Lilly may propose that it obtain an alternative type of
survey record. The OIG will consider Lilly’s proposal, and after considering Lilly’s proposal
shall, in its discretion, identify the type of survey records to be obtained.

     For each Covered Product, Lilly shall contract with the Survey Entity to conduct inquiries
into the content and subject matter of the detailing interactions. The OIG shall select and notify
the Survey Entity of a one week period within every other quarter of the Reporting Period for which
the surveys shall be conducted beginning in the second full

Corporate Integrity Agreement

Eli Lilly Company

24

 

quarter after the Effective Date. For each Covered Product, Lilly shall obtain records reflecting
the purported content and subject matter of detailing sessions during the identified week in all
regions across the United States.

     Prior to the start of the second Reporting Period and every Reporting Period thereafter, based
on the information provided and other information known to it, and after consultation with Lilly,
the OIG shall select up to three Government Reimbursed Products to be the basis for the review
outlined in this Section III.J and shall notify Lilly of its selection. These identified products
shall be known as the “Covered Products.” The parties have already identified the Covered Products
for the first Reporting Period.

     Lilly shall review the records obtained from the Survey Entity and shall identify any
instances in which the records appear to indicate that Covered Persons may have discussed and/or
disseminated information about off-label uses of the Covered Products. Lilly shall make findings
based on its review (Off-Label Findings) and shall take any responsive action it deems necessary.
If necessary for purposes of its review, Lilly shall endeavor to gather additional factual
information about the circumstances relating to any Off-Label Findings. As part of each Annual
Report, Lilly shall provide the OIG with copies of the underlying records of the detailing
interactions, a copy of Lilly’s Off-Label Findings, and a description of the action(s), if any,
Lilly took in response to the Off-Label Findings.

     K. Field Force Monitoring and Review Efforts

     To the extent not already accomplished, within 120 days after the Effective Date, Lilly shall
establish a Field Force Monitoring Program (FFMP) to evaluate and monitor field sales force
representatives’ interactions with HCPs. The FFMP shall be a formalized process designed to
directly observe the appropriateness of field sales force representative’s interactions with HCPs
and to identify potential off-label promotional activities.

     Under this program, Lilly compliance personnel or appropriately trained Lilly employees who
are not currently working in the marketing or the field sales organization shall conduct direct
field observations (Observations) of field sales force representatives to assess whether the
messages delivered and materials distributed to HCPs are consistent with Lilly’s Policies and
Procedures. These Observations shall be full day ride-alongs with field sales representatives, and
each Observation shall consist of directly observing all meetings between a sales representative
and HCPs during the workday. The

Corporate Integrity

Agreement Eli Lilly Company

25

 

Observations shall be scheduled throughout the year, randomly selected by Lilly compliance
personnel, include each therapeutic area and actively promoted product, and be conducted across the
United States. At the completion of each Observation, Lilly compliance personnel or the designee
shall prepare a report which includes:

	 	1)	 	the identity of the sales representative;
	 
	 	2)	 	the identity of the Lilly compliance professional or
other Lilly employee;
	 
	 	3)	 	the date and duration of the Observation;
	 
	 	4)	 	the product(s) promoted during the Observation;
	 
	 	5)	 	an overall assessment of compliance with Lilly policy; and
	 
	 	6)	 	the identification of any potential off-label promotional
activity by the field sales representative.

     Lilly compliance personnel shall conduct at least 50 full-day Observations during each
Reporting Period. The number of inspections conducted for each therapeutic area and product shall
be proportional in number to the size of each therapeutic area and product, and shall be conducted
across the United States.

     In the event that a compliance issue, including but not limited to a potential off-label
promotion or noncompliance with Lilly’s compliance program or policies and procedures, is
identified during any Observation, Lilly shall investigate the incident consistent with established
Policies and Procedures for the handling of investigations. As part of the formal investigation
procedures, findings shall be made and all necessary and appropriate responsive action (including
disciplinary action) and corrective action shall be taken. The Compliance Officer shall disclose
Reportable Events pursuant to Section III.H above, if applicable. Any compliance issues identified
during an Observation and any corrective action shall be recorded in the files of the compliance
department.

     Lilly shall include a summary of the FFMP and the results of the FFMP as part of each Annual
Report. As part of each Annual Report, Lilly also shall provide the OIG with copies of the
Observation report for any instances in which it was determined that improper promotion occurred
and a description of the action(s) that Lilly took as a result of such determinations. Lilly shall
make the Observation reports for all other Observations available to the OIG upon request.

Corporate Integrity Agreement

Eli Lilly Company

26

 

     L. Notice to Health Care Providers and Entities

     Within 90 days after the Effective Date, Lilly shall send, by first class mail, postage
prepaid and return receipt requested, a notice containing the language set forth below to all HCPs
and HCIs that Lilly currently details. This notice shall be dated and shall be signed by Lilly’s
Chief Executive Officer. The body of the letter shall state the following:

As you may be aware, Eli Lilly and Company (Lilly) recently entered into a global civil,
criminal, and administrative settlement with the United States and individual states in
connection of its promotion of its drug Zyprexa.

This letter provides you with additional information about the settlement, explains Lilly’s
commitments going forward, and provides you with access to information about those
commitments. In general terms, the Government alleged that Lilly unlawfully promoted the
drug Zyprexa for certain uses not approved by the Food & Drug Administration (FDA). To
resolve these matters, Lilly pled guilty to a misdemeanor criminal violation of the Federal
Food Drug and Cosmetic Act and agreed to pay more than $1 billion to the Federal Government
and state Medicaid programs. More information about this settlement may be found at the
following: [Lilly shall include a link to the USAO, OCL, and Eli Lilly websites in the
letter.]

As part of the federal settlement, Lilly also entered into a five-year corporate integrity
agreement with the Office of Inspector General of the U.S. Department of Health and Human
Services. The corporate integrity agreement is available at
http://oig.hhs.gov/fraud/cia/index.html. Under this agreement, Lilly agreed to
undertake certain obligations designed to promote compliance with Federal healthcare
program and FDA requirements. We also agreed to notify healthcare providers about the
settlement and inform them that they can report any questionable practices by Lilly’s
representatives to Lilly’s Compliance Department or the FDA.

Please call or email Lilly at 1-800-TBD or [Lilly shall insert website address in
the letter.] if you have questions about the settlement referenced above or to report any
instances in which you believe that a Lilly representative inappropriately promoted a
product or engaged in other questionable conduct. Alternatively, you may report any such
instances to the FDA’s Division of Drug Marketing, Advertising, and Communications at
301-796-1200. You should direct medical questions or concerns about the products to The
Lilly Answer Center at 

1-800-Lilly-Rx.

Corporate Integrity Agreement
Eli Lilly Company

27

 

We appreciate your time and attention. We are dedicated to ensuring that we bring you the
scientific and medical information you need to make well-informed decisions about whether
Lilly products are right for your patients.

     The Chief Compliance Officer (or a designee) shall maintain a log of all calls and messages
received in response to the notice. The log shall include a record and summary of each call and
message received (whether anonymous or not), the status of the call or message, and any corrective
action taken in response to the call or message. The disclosure log shall be made available to OIG
upon request. As part of the Implementation Report and each Annual Report, Lilly shall provide to
the OIG a summary of the calls and messages received.

     M. Reporting of Physician Payments

1. Phase I Reporting

     On or before August 1, 2009, Lilly shall post in a prominent position on its website an easily
accessible and readily searchable listing of all U.S.-based physicians and Related Entities (as
defined below in Section III.M.4) who or which received Phase I Payments (as defined below in
Section III.M.4) directly or indirectly from Lilly or Lilly USA during the first three months of
2009 and the aggregate value of such Payments.

     After the initial posting, 30 days after the end of each subsequent calendar quarter, Lilly
shall also post on its website a listing of updated information about all Phase I Payments provided
during the applicable calendar year during the preceding quarter(s). On or before May 1, 2010,
Lilly shall also post on its website a report of the cumulative value of Phase I Payments provided
to each physician and/or Related Entity during the preceding calendar year. The quarterly and
annual reports shall be easily accessible and readily searchable.

     Each
listing made pursuant to this Section III.M.1 or Sections III.M 2 or 3 below, shall
include a complete list of all individual physicians and Related Entities to whom or to which Lilly
or Lilly USA directly or indirectly made the Phase I, II, or III Payments (as applicable) in the
preceding calendar quarter or year (as applicable). Each listing shall be arranged alphabetically
according to the physicians’ last name or the name of the Related

Corporate Integrity
Agreement

 Eli Lilly Company

28

 

Entity. The Payment amounts in the lists shall be reported in $10,000 increments (e.g., $0 -
$10,000; $10,001- $20,000; etc.) For each physician, the applicable listing shall include the
following information: i) physician’s full name; ii) name of Related Entity (if applicable); iii)
city and state that the physician or the Related Entity has provided to Lilly for contact purposes;
and (iv) the aggregate value of the payment(s) in the preceding quarter(s) or year (as applicable).
If payments for multiple physicians have been made to one Related Entity, the aggregate value of
all payments to the Related Entity will be the reported amount.

          2. Phase II Reporting

     On or before August 1, 2010, Lilly shall post in a prominent position on its website an easily
accessible and readily searchable listing of all U.S.-based physicians and Related Entities (as
defined below in Section III.M.4) who provided or which received Phase II Payments (as defined
below in Section III.M.4) directly or indirectly from Lilly or Lilly USA during the first three
months of 2010 and the aggregate value of such Payments.

     After the initial posting, 30 days after the end of each subsequent calendar quarter, Lilly
shall also post on its website a listing of updated information about all Phase II Payments
provided during the applicable calendar year during the preceding quarter(s). On or before May 1,
2011, Lilly shall also post on its website a report of the cumulative value of Phase II Payments
provided to each physician and/or Related Entity during the preceding calendar year. The quarterly
and annual reports shall be easily accessible and readily searchable.

          3. Phase III Reporting

     On or before August 1, 2011, Lilly shall post in a prominent position on its website an easily
accessible and readily searchable listing of all U.S.-based physicians and Related Entities (as
defined below in Section III.M.4) who or which received Phase III Payments (as defined below in
Section III.M.4) directly or indirectly from Lilly or Lilly USA during the first three months of
2011 and the aggregate value of such Payments.

     After the initial posting, 30 days after the end of each subsequent calendar quarter, Lilly
shall also post on its website a listing of updated information about all Phase III Payments
provided during the applicable calendar year during the preceding quarter(s). On or before May 1,
2012, Lilly shall also post on its website a report of the cumulative

Corporate Integrity Agreement

Eli Lilly Company

29

 

value of Phase III Payments provided to each physician and/or Related Entity during the preceding
calendar year. Thereafter, on or before May 1 of each subsequent year, Lilly shall post a report of
the cumulative value of Payments provided to each physician and/or Related Entity during the
preceding calendar year. The quarterly and annual reports shall be easily accessible and readily
searchable.

          4. Definitions and Miscellaneous Provisions

     Lilly shall continue to make each annual listing and the most recent quarterly listing of
Phase I, Phase II, and Phase III Reporting available on its website at least throughout the term of
this CIA. Lilly shall retain and make available to OIG, upon request, all work papers, supporting
documentation, correspondence, and records related to all applicable Payments and to the annual and
quarterly listings of Payments. Nothing in this Section III.M affects the responsibility of Lilly
to comply with (or liability for noncompliance with) all applicable Federal health care program
requirements and state laws as they relate to all applicable Payments made to physicians or Related
Entities.

     If the proposed Physician Payments Sunshine Act of 2008 or similar legislation is enacted, the
OIG shall determine whether the purposes of this Section III.M are reasonably satisfied by Lilly’s
compliance with such legislation. In such case, and in its sole discretion, the OIG may agree to
modify or terminate provisions of Section III.M as appropriate.

     For purposes of this Section III.M, the term “Phase I Payments” is defined as all honoraria
payments made in connection with physicians serving as speakers, participating in speaker training,
or serving as consultants (including participating in advisory boards, providing training to Lilly
employees, or providing ad hoc advising.)

     For purposes of this Section III.M, the term “Phase II Payments” is defined as all payments
(including, for example, honoraria payments, other payments, and reimbursement for lodging, travel
and other expenses) made in connection with physicians serving as speakers, participating in
speaker training, or serving as consultants (including participating in advisory boards, providing
training to Lilly employees, or providing ad hoc advising).

     For purposes of this Section III.M, the term “Phase III Payments” is defined to include all
payments or transfers of value (whether in cash or in kind) made to physicians. The term also
includes all payments or transfers of value made to Related Entities on

Corporate Integrity Agreement

Eli Lilly Company

30

 

behalf of, at the request of, for the benefit or use of, or under the name of a physician for whom
Lilly would otherwise report a Payment if made directly to the physician. Phase III Payments
includes all Phase I and Phase II Payments. Phase III Payments include, for example, payments or
compensation for services rendered; grants; fees; and payments relating to research or education.
The term Phase III Payments also includes payment or reimbursement for food, entertainment, gifts,
trips or travel, product(s)/item(s) provided for less than fair market value, or other economic
benefit paid or transferred. Phase III Payments do not include: i) samples of drug products that
meet the definition set forth in 21 C.F.R. § 203.3(i), or ii) discounts, rebates, or other pricing
terms.

     For purposes of this Section III.M, the term “Related Entity” is defined to be any entity by
or in which any physician receiving Phase I, II, or III Payments is employed, has tenure, or has an
ownership interest.

IV. Changes to Business Units or Locations

     A. Change or Closure of Unit or Location. In the event that, after the Effective
Date, Lilly or Lilly USA changes locations or closes a business unit or location related to
Promotional and Product Services Related Functions, Lilly shall notify OIG of this fact as
soon as possible, but no later than within 30 days after the date of change or closure of the
location.

     B. Purchase or Establishment of New Unit or Location. In the event that, after the
Effective Date, Lilly or Lilly USA purchases or establishes a new business unit or
location related to Promotional and Product Services Related Functions, Lilly shall notify
OIG no later than the date that the purchase or establishment is publicly disclosed by
Lilly. This notification shall include the address of the new business unit or location,
phone number, fax number, Federal health care program provider or supplier number (if
applicable), and the name and address of the contractor that issued each number (if
applicable). Each new business unit or location and all Covered Persons at each new
business unit or location shall be subject to the applicable requirements of this CIA.

     C. Sale of Unit or Location. In the event that, after the Effective Date,
Lilly or Lilly USA proposes to sell any or all of its business units or locations related to the
Promotional and Product Services-Related Functions that are subject to this CIA, Lilly shall notify
OIG of the proposed sale no later than the date the sale is publicly disclosed by Lilly. This
notification shall include a description of the business unit or location to be sold, a brief
description of the terms of the sale, and the name and contact information of

Corporate Integrity Agreement

Eli Lilly Company

31

 

the prospective purchaser. This CIA shall be binding on the purchaser of such business unit or
location, unless otherwise determined and agreed to in writing by the OIG.

V. Implementation and Annual Reports

     A. Implementation Report. Within 150 days after the Effective Date, Lilly shall submit
a written report to OIG summarizing the status of its implementation of the requirements of this
CIA (Implementation Report). The Implementation Report shall, at a minimum, include:

          1. the name, address, phone number, and position description of the
Compliance Officer required by Section III.A.1, and a summary of other noncompliance
job responsibilities the Compliance Officer may have;

          2. the names and positions of the members of the Compliance Committee
required by Section III.A.2;

          3. the names of the members of the Committee of the Board referenced in
Section III.A.3;

          4. the names and positions of the Certifying Employees required by Section
III.A.4;

          5. a copy of Lilly’s Code of Conduct required by Section III.B.1;

          6. the number of Covered Persons required to complete the Code of
Conduct certification required by Section III.B.1, the percentage of Covered Persons who
have completed such certification, and an explanation of any exceptions (the
documentation supporting this information shall be available to OIG, upon request);

          7. (a) a copy of the letter (including all attachments) required by Sections
II.C.6 and III.B.2 sent to each party employing Third Party Personnel; (b) a list of all such
existing agreements; and (c) a description of the entities’ response to Lilly’s letter;

          8. to the extent not already provided to the OIG, a copy of all Policies and
Procedures required by Section III.B.3;

Corporate Integrity Agreement

Eli Lilly Company

32

 

          9. the following information regarding each type of training required by Section III.C:

a. a description of such training, including a summary of the topics
covered, the length of sessions, and a schedule of training sessions;
and

b. the number of Covered Persons required to be trained, percentage
of Covered Persons actually trained, and an explanation of any
exceptions.

A copy of all training materials and the documentation supporting this information shall be
available to OIG, upon request;

          10. the following information regarding the IRO(s): (a) identity, address,
and phone number; (b) a copy of the engagement letter; and (c) a summary and
description of any and all current and prior engagements and agreements between Lilly
and the IRO;

          11. a certification from the IRO regarding its professional independence
and objectivity with respect to Lilly;

          12. a description of the Disclosure Program required by Section III.E;

          13. a description of the process by which Lilly fulfills the requirements of
Section III.F regarding Ineligible Persons;

          14. the name, title, and responsibilities of any person who is determined to
be an Ineligible Person under Section III.F; the actions taken in response to the screening
and removal obligations set forth in Section III.F;

          15. a certification by the Chief Compliance Officer that the notice required
by  Section III.L was mailed to each HCP and HCI, the number of HCPs and HCIs that
received a copy of the notice, a sample copy of the notice required by Section III.L, and a
summary of the calls or messages received in response to the notice;

Corporate Integrity Agreement 

Eli Lilly Company

33

 

          16. a certification from the Chief Compliance Officer that, if required
under Section III.M and to the best of his/her knowledge, information regarding Payments
has been posted on Lilly’s website as required by Section III.M;

          17. a list of all of Lilly’s U.S. locations (including locations and mailing
addresses) at which it performs Promotional and Product Services Related Functions; the
corresponding name under which each location is doing business; the corresponding
phone numbers and fax numbers; each location’s Federal health care program provider or
supplier number(s) (if applicable), and the name and address of each Federal health care
program contractor to which Lilly currently submits claims (if applicable);

          18. a description of Lilly’s corporate structure, including identification of
any parent and sister companies, subsidiaries, and their respective lines of business; and

          19. the certifications required by Section V.C.

     B. Annual Reports. Lilly shall submit to OIG annually a report with respect to the
status of, and findings regarding, Lilly’s compliance activities for each of the five Reporting
Periods (Annual Report).

Each Annual Report shall include, at a minimum:

          1. an explanation of any change in the identity, position description, or
other noncompliance job responsibilities of the Chief Compliance Officer and any change
in the membership of the Compliance Committee, the compliance Committee of the
Board of Directors, or the group of Certifying Employees described in Sections III.A.2-4,
and a copy of the Compliance Program Review Report described in Section III.A.3;

          2. a summary of any significant changes or amendments to the Policies and
Procedures required by Section III.B and the reasons for such changes (e.g., change in
applicable requirements);

          3. the number of Covered
Persons required to complete the Code of Conduct certification required by Section III.B.1, the percentage of Covered Persons who have
completed such certification, and an explanation of any exceptions (the documentation supporting
this information shall be available to OIG, upon request);

Corporate Integrity Agreement

Eli Lilly Company

34

 

          4. (a) a copy of the letter (including all attachments) required by Sections II.C.6 and
III.B.2 sent to each entity employing Third Party Personnel; (b) a list of all
such existing agreements; and (c) a description of the entities’ response to Lilly’s letter;

          5.
the following information regarding each type of training required by
Section III.C:

a. a description of such training, including a summary of the topics
covered, the length of sessions, and a schedule of training sessions; and

b. the number of Covered Persons required to be trained, percentage of
Covered Persons actually trained, and an explanation of any exceptions.

A copy of all training materials and the documentation supporting this information shall be
available to OIG, upon request.

          6.
a complete copy of all reports prepared pursuant to Section III.D, along
with a copy of the IRO’s engagement letter (if applicable);

          7.
Lilly’s response and corrective action plan(s) related to any issues raised by the reports
prepared pursuant to Section III.D;

          8. a summary and description of any and all current and prior engagements and agreements
between Lilly and the IRO, if different from what was submitted as part of the Implementation
Report;

          9. a certification from the IRO regarding its professional independence and objectivity with
respect to Lilly;

          10.
a summary of the disclosures in the disclosure log required by
Section III.E that relate to Federal health care programs;

          11.
any changes to the process by which Lilly fulfills the requirements
of Section III.F regarding Ineligible Persons;

          12. the name, title, and responsibilities of any person who is determined to

Corporate Integrity Agreement

Eli Lilly Company

35

 

be an Ineligible Person under Section III.F; the actions taken by Lilly in response to the
screening and removal obligations set forth in Section III.F;

          13. a summary describing any ongoing investigation or legal proceeding required to have
been reported pursuant to Section III.G. The summary shall include a
 description of the allegation, the identity of the investigating or prosecuting agency, and
 the status of such investigation or legal proceeding;

          14.
a summary of Reportable Events (as defined in Section III.H) identified during the
Reporting Period and the status of any corrective and preventative action relating to all such
Reportable Events;

          15. a summary describing any written communication with the FDA required to have been reported pursuant to Section III.I. This summary shall include a description of the matter and the
status of the matter;

          16. all information required by Section III.J;

          17. all information required by Section III.K;

          18. a summary of the calls and messages received in response to the notice required
by Section III.L and the disposition of those calls and messages

          19. a description of all changes to the most recently provided list of Lilly’s
locations (including addresses) as required by Section V.A.17; the
corresponding name under which each location is doing business; the
corresponding phone numbers and fax numbers; each location’s Federal health
care program provider or supplier number(s) (if applicable), and the name and
address of each Federal health care program contractor to which Lilly currently
submits claims (if applicable); and

          20. the certifications required by Section V.C.

     The first Annual Report shall be received by OIG no later than 60 days after the end of the
first Reporting Period. Subsequent Annual Reports shall be received by OIG
no later than the anniversary date of the due date of the first Annual Report.

Corporate
Integrity Agreement
Eli Lilly Company

36

 

     C. Certifications. The following certifications shall be included in the
Implementation Report and Annual Reports:

          1.
Certifying Employees: In each Annual Report, Lilly shall include the certifications of
Certifying Employees as required by Section III.A.4;

          2.
Chief Compliance Officer: In the Implementation Report and Annual
Reports, Lilly shall include the following individual certification by the Chief Compliance Officer:

               a. he or she has reviewed the Report and has made reasonable inquiry regarding its content
and believes that the information in the Report is accurate and truthful;

               b. to the best of his or her knowledge, except as otherwise described in the applicable
report, Lilly is in compliance with the Federal health care program and FDA requirements and the obligations of the CIA;

               c. to the best of his or her knowledge, Lilly has complied with its obligations under the
Settlement Agreement: (a) not to resubmit to any Federal health care program payors any previously
denied claims related to the Covered Conduct addressed in the Settlement Agreement, and not to
appeal any such denials of claims; (b) not to charge to or otherwise seek payment from federal or
state payors for unallowable costs (as defined in the Settlement Agreement); and (c) to identify
and adjust any past charges or claims for unallowable costs;

               d. Lilly’s: 1) Policies and Procedures as referenced in Section
III.B.3 above; 2) templates for standardized contracts and other similar documents; and 3) the
training materials used for purposes of Section III.C all have been reviewed by
competent legal counsel and/or legal personnel working at their direction and have been found to
be in compliance with all applicable Federal health care program and FDA
requirements. In addition, Lilly’s promotional materials containing claims or information
about Government Reimbursed Products and other materials and information intended to be
disseminated outside Lilly have been reviewed by competent regulatory, medical, and/or legal
personnel in accordance with applicable Policies and Procedures to ensure that legal, medical, and
regulatory concerns are properly addressed and are elevated when
appropriate, and that the materials and information when finally approved are in
compliance with all applicable Federal health care program and FDA requirements. If the

Corporate Integrity Agreement

Eli Lilly Company

37

 

applicable legal requirements have not changed, after the initial review of the documents
listed above, only material changes to the documents must be reviewed by competent regulatory,
medical, and/or legal personnel. The certification shall include a description of the document(s)
reviewed and approximately when the review was completed. The documentation supporting this
certification shall be available to OIG, upon request; and

               e. Lilly’s call plans for Government Reimbursed Products were reviewed at least once during the
Reporting Period (consistent with Section III.B.3.g) and, for each product the call plans were
found to be consistent with Lilly’s policy objectives as referenced above in Section III.B.3.g.

     D. Designation of Information. Lilly shall clearly identify any portions of its submissions
that it believes are trade secrets, or information that is commercial or financial and privileged
or confidential, and therefore potentially exempt from disclosure under the Freedom of Information
Act (FOIA), 5 U.S.C. § 552. Lilly shall refrain from identifying any information as exempt from
disclosure if that information does not meet the criteria for exemption from disclosure under FOIA.

VI.
Notifications and
Submission of Reports

     Unless otherwise stated in writing after the Effective Date, all notifications and reports
required under this CIA shall be submitted to the following entities:

	 	 	 	 	 
	 

	 	OIG:
	 	Administrative and Civil Remedies Branch
	 

	 	 	 	Office of Counsel to the Inspector General
	 

	 	 	 	Office of Inspector General
	 

	 	 	 	U.S. Department of Health and Human Services
	 

	 	 	 	Cohen Building, Room 5527
	 

	 	 	 	330 Independence Avenue, S.W.
	 

	 	 	 	Washington, DC 20201
	 

	 	 	 	Telephone: 202.619.2078
	 

	 	 	 	Facsimile: 202.205.0604
	 
	 	 	 	 
	 

	 	Lilly:
	 	Chief Compliance Officer
	 

	 	 	 	Eli Lilly and Company
	 

	 	 	 	Lilly Corporate Center, DC 1114
	 

	 	 	 	Indianapolis, IN 46285
	 

	 	 	 	Telephone: 317.276.9937
	 

	 	 	 	Facsimile: 317.655.1921

Corporate Integrity Agreement

Eli Lilly Company

38

 

Unless otherwise specified, all notifications and reports required by this CIA may be made by
certified mail, overnight mail, hand delivery, or other means, provided that there
is proof that such notification was received. For purposes of this requirement, internal
facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG,
Lilly may be required to provide OIG with an electronic copy of each notification or report
required by this CIA in searchable portable document format (pdf), either instead of or in
addition to, a paper copy.

VII.
OIG Inspection,
Audit, and Review Rights

     In addition to any other rights OIG may have by statute, regulation, or contract,
OIG or its duly authorized representative(s) may examine or request
copies of Lilly’s
books, records, and other documents and supporting materials and/or conduct on-site
reviews of any of Lilly’s locations for the purpose of verifying and evaluating: (a) Lilly’s
compliance with the terms of this CIA; and (b) Lilly’s compliance with the requirements of
the Federal health care programs in which it participates and with all applicable FDA
requirements. The documentation described above shall be made
available by Lilly to OIG or its duly
authorized representative(s) at all reasonable times for inspection, audit, or reproduction.
Furthermore, for purposes of this provision, OIG or its duly authorized representative(s) may
interview any of Lilly’s employees, contractors, or agents who
consent to be interviewed at the individual’s place of business during normal business
hours or at such other place and time as may be mutually agreed upon between the individual and
OIG. Lilly shall assist OIG or its duly authorized representative(s) in contacting and arranging
interviews with such individuals upon OIG’s request. Lilly’s employees may elect to be
interviewed with or without a representative of Lilly present.

VIII.
Document and Record
Retention

     Lilly shall maintain for inspection all documents and records relating to reimbursement from
the Federal health care programs, or to compliance with this CIA, for six years (or longer if
otherwise required by law) from the Effective Date.

Corporate Integrity Agreement

Eli Lilly Company

39

 

IX. Disclosures

     Consistent with HHS’s FOIA procedures, set forth in 45 C.F.R. Part 5, OIG shall make a
reasonable effort to notify Lilly prior to any release by OIG of information submitted by Lilly
pursuant to its obligations under this CIA and identified upon submission by Lilly as trade
secrets, or information that is commercial or financial and privileged or confidential, under the
FOIA rules. With respect to such releases, Lilly shall have the rights set forth at 45 C.F.R. §
5.65(d).

X.
Breach and Default
Provisions

     Lilly is expected to fully and timely comply with all of its CIA obligations. The breach and
default remedies available to the OIG under this Section X do not preempt or limit any actions
that individual States may take against Lilly under applicable legal authorities or under any
applicable settlement agreement or consent decree between the State and Lilly.

     A. Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual
remedy, Lilly and OIG hereby agree that failure to comply with certain obligations as set forth in
this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to
as “Stipulated Penalties”) in accordance with the following provisions.

          1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the
obligation became due) for each day Lilly fails to establish, implement, or accomplish any of the
following obligations as described in Section III:

	 	 	 
	 

	 	a. a Compliance Officer;
	 
	 	 
	 

	 	b. a Compliance Committee;
	 
	 	 
	 

	 	c. the resolution from the Committee of the Board;
	 
	 	 
	 

	 	d. a written Code of Conduct;
	 
	 	 
	 

	 	e. written Policies and Procedures;
	 
	 	 
	 

	 	f. the training of Covered Persons and Relevant Covered Persons;
	 
	 	 
	 

	 	g. a Disclosure Program;

Corporate Integrity Agreement

Eli Lilly Company

40

 

	 	 	 
	 

	 	h. Ineligible Persons screening and removal requirements;
	 
	 	 
	 

	 	i. notification of Government investigations or legal proceedings;
	 
	 	 
	 

	 	j. notification of written
communications with FDA as required by Section III.I;
	 
	 	 
	 

	 	k. a review of records reflecting the content of detailing sessions;
	 
	 	 
	 

	 	l. a program for FFMP;
	 
	 	 
	 

	 	l. notification to HCPs and HCIs as required by Section III.L;
	 
	 	 
	 

	 	m. posting of any Payments as required by Section III.M.

          2. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the
obligation became due) for each day Lilly fails to engage an IRO, as required in Section III.D and
Appendices A-B.

          3.
A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the
obligation became due) for each day Lilly fails to submit the Implementation Report or the Annual
Reports to OIG in accordance with the requirements of Section V by the deadlines for submission.

          4.
A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the
obligation became due) for each day Lilly fails to submit the annual IRO
Review Report(s) in accordance with the requirements of
Section III.D and Appendices A-B.

          5. A Stipulated Penalty of $1,500 for each day Lilly fails to grant access as required in
Section VII. (This Stipulated Penalty shall begin to accrue on the date Lilly fails to grant
access.)

          6. A Stipulated Penalty of $5,000 for each false certification submitted by or on behalf of
Lilly as part of its Implementation Report, Annual Report, additional documentation to a report (as
requested by the OIG), or otherwise required by this CIA.

Corporate Integrity Agreement

Eli Lilly Company

41

 

          7. A Stipulated Penalty of $1,000 for each day Lilly fails to comply fully and adequately with
any obligation of this CIA. OIG shall provide notice to Lilly, stating the specific grounds for its
determination that Lilly has failed to comply fully and adequately with the CIA obligation(s) at
issue and steps Lilly shall take to comply with the CIA. (This Stipulated Penalty shall begin to
accrue 10 days after Lilly receives this notice from OIG of the failure to comply.) A Stipulated
Penalty as described in this Subsection shall not be demanded for any violation for which OIG has
sought a Stipulated Penalty under Subsections 1-6 of this Section.

     B. Timely Written Requests for Extensions. Lilly may, in advance of the due
date, submit a timely written request for an extension of time to perform any act or file any
notification or report required by this CIA. Notwithstanding any other provision in this Section,
if OIG grants the timely written request with respect to an act, notification, or report,
Stipulated Penalties for failure to perform the act or file the notification or report shall not
begin to accrue until one day after Lilly fails to meet the revised deadline set by OIG.
Notwithstanding any other provision in this Section, if OIG denies such a timely written request,
Stipulated Penalties for failure to perform the act or file the notification or report shall not
begin to accrue until three business days after Lilly receives OIG’s written denial of such request
or the original due date, whichever is later. A “timely written request” is defined as a request in
writing received by OIG at least five business days prior to the date by which any act is due to be
performed or any notification or report is due to be filed.

     C. Payment of Stipulated Penalties.

          1.
Demand Letter. Upon a finding that Lilly has failed to comply with any of the obligations
described in Section X.A and after determining that Stipulated Penalties are appropriate, OIG shall
notify Lilly of: (a) Lilly’s failure to comply; and (b) OIG’s exercise of its contractual right to
demand payment of the Stipulated Penalties (this notification is referred to as the “Demand
Letter”).

          2.
Response to Demand Letter. Within 10 days after the
receipt of the Demand Letter, Lilly shall either: (a) cure the breach to OIG’s satisfaction and pay the
applicable Stipulated Penalties; or (b) request a hearing before an HHS administrative
law judge (ALJ) to dispute OIG’s determination of noncompliance, pursuant to the agreed
upon provisions set forth below in Section X.E. In the event Lilly elects to request an ALJ
hearing, the Stipulated Penalties shall continue to accrue until Lilly cures, to OIG’s
satisfaction, the alleged breach in dispute. Failure to respond to the Demand Letter in one

Corporate Integrity Agreement

Eli Lilly Company

42

 

of these two manners within the allowed time period shall be considered a material breach of this
CIA and shall be grounds for exclusion under Section X.D.

          3.
Form of Payment. Payment of the Stipulated Penalties shall be made by electronic funds
transfer to an account specified by OIG in the Demand Letter.

          4. Independence from Material Breach Determination. Except as set forth
in Section X.D.1.c, these provisions for payment of Stipulated Penalties shall not affect or
otherwise set a standard for OIG’s decision that Lilly has materially breached this CIA,
which decision shall be made at OIG’s discretion and shall be governed by the provisions
in Section X.D, below.

     D. Exclusion for Material Breach of this CIA.

          1. Definition of Material Breach. A material breach of this CIA means:

a. a failure by Lilly to report a Reportable Event and take corrective
action, as required in Section III.H;

b. a repeated or flagrant violation of the obligations under this CIA,
including, but not limited to, the obligations addressed in Section
X.A;

c. a failure to respond to a Demand Letter concerning the payment
of Stipulated Penalties in accordance with Section X.C;

d. a failure to engage and use an IRO in accordance with Section
III.D; or

e. a failure of the Committee of the Board to issue a resolution in
accordance with Section III.A.3.

          2. Notice of Material Breach and Intent to Exclude. The parties agree that
a material breach of this CIA by Lilly constitutes an independent basis for Lilly’s
exclusion from participation in the Federal health care programs. Upon a determination
by OIG that Lilly has materially breached this CIA and that exclusion is the appropriate
remedy, OIG shall notify Lilly of: (a) Lilly’s material breach; and (b) OIG’s intent to
exercise its contractual right to impose exclusion (this notification is hereinafter referred

Corporate
Integrity Agreement

Eli Lilly Company

43

 

to as the “Notice of Material Breach and Intent to Exclude”).

          3.
Opportunity to Cure. Lilly shall have 30 days from the date of receipt of
the Notice of Material Breach and Intent to Exclude to demonstrate to OIG’s satisfaction
that:

a. Lilly is in compliance with the obligations of the CIA cited by
OIG as being the basis for the material breach;

b. the alleged material breach has been cured; or

c. the alleged material breach cannot be cured within the 30-day
period, but that: (i) Lilly has begun to take action to cure the
material breach; (ii) Lilly is pursuing such action with due diligence;
and (iii) Lilly has provided to OIG a reasonable timetable for curing
the material breach.

          4. Exclusion Letter. If, at the conclusion of the 30-day period, Lilly fails to
satisfy the requirements of Section X.D.3, OIG may exclude Lilly from participation in
the Federal health care programs. OIG shall notify Lilly in writing of its determination to
exclude Lilly (this letter shall be referred to hereinafter as the “Exclusion Letter”).
Subject to the Dispute Resolution provisions in Section X.E, below, the exclusion shall go
into effect 30 days after the date of Lilly’s receipt of the Exclusion Letter. The exclusion
shall have national effect and shall also apply to all other Federal procurement and
nonprocurement programs. Reinstatement to program participation is not automatic.
After the end of the period of exclusion, Lilly may apply for reinstatement by submitting
a written request for reinstatement in accordance with the provisions at 42 C.F.R. §§ 1001.3001-.3004.

     E. Dispute Resolution

          1. Review Rights. Upon OIG’s delivery to Lilly of its Demand Letter or of its Exclusion
Letter, and as an agreed-upon contractual remedy for the resolution of disputes arising under this
CIA, Lilly shall be afforded certain review rights comparable to the ones that are provided in 42
U.S.C. § 1320a-7(f) and 42 C.F.R. Part 1005 as if they applied to the Stipulated Penalties or
exclusion sought pursuant to this CIA. Specifically, OIG’s determination to demand payment of
Stipulated Penalties or to seek exclusion shall be subject to review by an HHS ALJ and, in the
event of an appeal, the HHS

Corporate Integrity Agreement

Eli Lilly Company

44

 

Departmental Appeals Board (DAB), in a manner consistent with the provisions in 42 C.F.R. §
1005.2-1005.21. Notwithstanding the language in 42 C.F.R. § 1005.2(c), the request for a hearing
involving Stipulated Penalties shall be made within 10 days after receipt of the Demand Letter and
the request for a hearing involving exclusion shall be made within 25 days after receipt of the
Exclusion Letter.

          2. Stipulated Penalties Review. Notwithstanding any provision of Title 42
of the United States Code or Title 42 of the Code of Federal Regulations, the only issues
in a proceeding for Stipulated Penalties under this CIA shall be: (a) whether Lilly was in
full and timely compliance with the obligations of this CIA for which OIG demands
payment; and (b) the period of noncompliance. Lilly shall have the burden of proving its
full and timely compliance and the steps taken to cure the noncompliance, if any. OIG
shall not have the right to appeal to the DAB an adverse ALJ decision related to
Stipulated Penalties. If the ALJ agrees with OIG with regard to a finding of a breach of
this CIA and orders Lilly to pay Stipulated Penalties, such Stipulated Penalties shall
become due and payable 20 days after the ALJ issues such a decision unless Lilly
requests review of the ALJ decision by the DAB. If the ALJ decision is properly
appealed to the DAB and the DAB upholds the determination of OIG, the Stipulated
Penalties shall become due and payable 20 days after the DAB issues its decision.

          3. Exclusion Review. Notwithstanding any provision of Title 42 of the
United States Code or Title 42 of the Code of Federal Regulations, the only issues in a
proceeding for exclusion based on a material breach of this CIA shall be:

a. whether Lilly was in material breach of this CIA;

b. whether such breach was continuing on the date of the Exclusion
Letter; and

c. whether the alleged material breach could not have been cured
within the 30-day period, but that: (i) Lilly had begun to take action
to cure the material breach within that period; (ii) Lilly has pursued
and is pursuing such action with due diligence; and (iii) Lilly
provided to OIG within that period a reasonable timetable for curing the
material breach and Lilly has followed the timetable.

          For purposes of the exclusion herein, exclusion shall take effect only after an ALJ decision
favorable to OIG, or, if the ALJ rules for Lilly, only after a DAB

Corporate Integrity Agreement

Eli Lilly Company

45

 

decision in favor of OIG. Lilly’s election of its contractual right to appeal to the DAB shall not
abrogate OIG’s authority to exclude Lilly upon the issuance of an ALJ’s decision in favor of OIG.
If the ALJ sustains the determination of OIG and determines that exclusion is authorized, such
exclusion shall take effect 20 days after the ALJ issues such a decision, notwithstanding that
Lilly may request review of the ALJ decision by the DAB. If the DAB finds in favor of OIG after an
ALJ decision adverse to OIG, the exclusion shall take effect 20 days after the DAB decision. Lilly
shall waive its right to any notice of such an exclusion if a decision upholding the exclusion is
rendered by the ALJ or DAB. If the DAB finds in favor of Lilly, Lilly shall be reinstated effective
on the date of the original exclusion.

          4. Finality of Decision. The review by an ALJ or DAB provided for above shall not be
considered to be an appeal right arising under any statutes or regulations. Consequently, the
parties to this CIA agree that the DAB’s decision (or the ALJ’s decision if not appealed) shall be
considered final for all purposes under this CIA.

XI.
Effective and
Binding Agreement

     Lilly and OIG agree as follows:

     A. This CIA shall be binding on the successors, assigns, and transferees of Lilly;

     B. This CIA shall become final and binding on the date the final signature is
obtained on the CIA;

     C. This CIA constitutes the complete agreement between the parties and may not
be amended except by written consent of the parties to this CIA;

     D. The undersigned Lilly signatories represent and warrant that they are
authorized to execute this CIA. The undersigned OIG signatory represents that he is
signing this CIA in his official capacity and that he is authorized to execute this CIA; and

     E. This CIA may be executed in counterparts, each of which constitutes an original and all of
which constitute one and the same CIA. Facsimiles of signatures shall constitute acceptable,
binding signatures for purposes of this CIA.

Corporate Integrity Agreement

Eli Lilly Company

46

 

On Behalf of Eli Lilly and Company

	 	 	 
	/s/ Robert A. Armitage

	 	14 January 2009
	 

	 	 
	Robert A. Armitage

	 	Date
	Senior Vice President and General Counsel
	 	 
	 
	 	 
	/s/ Anne Nobles

	 	1/14/09
	 

	 	 
	Anne Nobles

	 	Date
	Lilly Chief Compliance Officer
	 	 
	 
	 	 
	/s/ Paul Kalb

	 	1/14/09
	 

	 	 
	Paul Kalb

	 	Date
	Kristin Koehler
	 	 
	Counsel for Eli Lilly and Company
	 	 

Corporate Integrity Agreement

Eli Lilly Company

47

 

On Behalf of the Office of Inspector General

of the Department of Health and Human Services

	 	 	 
	/s/ Gregory E. Demske

	 	1/14/09
	 

	 	 
	Gregory E. Demske

	 	DATE
	Assistant Inspector General for Legal Affairs
	 	 
	Office of Inspector General
	 	 
	U. S. Department of Health and Human Services
	 	 

Corporate Integrity Agreement

Eli Lilly Company

48

 

APPENDIX A

INDEPENDENT REVIEW ORGANIZATION

This Appendix contains the requirements relating to the Independent Review Organization
(IRO) required by Section III.D of the CIA.

			
	A.	 	IRO Engagement

      Lilly shall engage an IRO that possesses the qualifications set forth in Paragraph
B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct
the review in a professionally independent and objective fashion, as set forth in Paragraph
D. Within 30 days after OIG receives written notice of the identity of the selected IRO,
OIG will notify Lilly if the IRO is unacceptable. Absent notification from OIG that the
IRO is unacceptable, Lilly may continue to engage the IRO.

     If Lilly engages a new IRO during the term of the CIA, this IRO shall also meet the
requirements of this Appendix. If a new IRO is engaged, Lilly shall submit the information
identified in Section V.A.8 of the CIA to OIG within 30 days of engagement of the IRO. Within 30
days after OIG receives written notice of the identity of the selected IRO, OIG will notify Lilly
if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Lilly may
continue to engage the IRO.

			
	B.	 	IRO Qualifications.

The IRO shall:

     1. assign individuals to conduct the Promotional and Product Services Review
who have expertise in all applicable Federal health care program and FDA requirements
relating to Promotional and Product Services Related Functions. The assigned
individuals shall also be knowledgeable about the general requirements of the Federal
health care program(s) under which Lilly products are reimbursed;

     2. assign individuals to design and select the samples for the Transaction Reviews
who are knowledgeable about the appropriate statistical sampling techniques; and

     3. have sufficient staff and resources to conduct the reviews required by the CIA
on a timely basis.

Appendix A

Eli Lilly CIA

1

 

			
	C.	 	IRO Responsibilities.

 The IRO shall:

     1. perform each Promotional and Product Services Review in accordance with the
specific requirements of the CIA;

     2. follow all applicable Federal health care program and FDA requirements in
making assessments in each Promotional and Product Services Review;

     3.
if in doubt of the application of a particular Federal health care
program or FDA requirement, policy, or regulation, request
clarification from the appropriate authority (e.g., CMS or FDA);

     4. respond to all OIG inquires in a prompt, objective, and factual manner; and

     5. prepare timely, clear, well-written reports that include all the information
required by Appendix B to the CIA.

			
	D.	 	IRO Independence and Objectivity.

The IRO must perform the Promotional and Product Services Review in a professionally independent
and objective fashion, as appropriate to the nature of the engagement, taking into account any
other business relationships or engagements that may exist between the IRO and Lilly.

			
	E.	 	IRO Removal/Termination.

     1. Lilly Termination of IRO. If Lilly terminates its IRO during the course of the
engagement, Lilly must submit a notice explaining its reasons to OIG no later than 30
days after termination. Lilly must engage a new IRO in accordance with Paragraph A of
this Appendix.

     2. OIG Removal of IRO. In the event OIG has reason to believe that the IRO does
not possess the qualifications described in Paragraph B, is not independent and/or
objective as set forth in Paragraph D, or has failed to carry out its responsibilities as
described in Paragraph C, OIG may, at its sole discretion, require Lilly to engage a new
IRO in accordance with Paragraph A of this Appendix.

     Prior to requiring Lilly to engage a new IRO, OIG shall notify Lilly of its intent to do so
and provide a written explanation of why OIG believes such a step is necessary. To resolve any
concerns raised by OIG, Lilly may request a meeting with OIG to discuss any aspect of the IRO’s
qualifications, independence or performance of its responsibilities and to present additional
information regarding these matters. Lilly shall provide any additional information as may be
requested by OIG under this Paragraph in an expedited manner. OIG will attempt in good faith to
resolve any differences regarding the IRO with Lilly prior to requiring Lilly to terminate the IRO.
However, the final determination as to whether or not to require Lilly to engage a new IRO shall be made at the sole discretion of
OIG.

Appendix A

Eli Lilly CIA

2

 

Appendix B to CIA

Promotional and Product Services Review

			
	I.	 	Promotional and Product Services Review, General Description

As specified more fully below, Lilly shall retain an Independent Review Organization (IRO) to
perform reviews to assist Lilly in assessing and evaluating its systems, processes, policies,
procedures, and practices related to Lilly’s Promotional and Product Services Related Functions
(Promotional and Product Services Review). The Promotional and Product Services Review shall
consist of two components - a systems review (the “Promotional and Product Services Systems Review”
or “Systems Review”), and a transactions review (the “Promotional and Product Services Transactions
Review” or “Transactions Review”) as described more fully below. Lilly may engage, at its
discretion, a single IRO to perform both components of the Promotional and Product Services Review
provided that the entity has the necessary expertise and capabilities to perform both.

     If there are no material changes in Lilly’s systems, processes, policies, and procedures
relating to Promotional and Product Services Related Functions, the IRO shall perform the
Promotional and Product Services Systems Review for the first and fourth Reporting Periods. If
Lilly materially changes its systems, processes, policies, and procedures relating to Promotional
and Product Services Related Functions, the IRO shall perform a Promotional and Product Services
Systems Review for the Reporting Period(s) in which such changes were made in addition to
conducting the Review for the first and fourth Reporting Periods. The additional Systems Review(s)
shall consist of: 1) an identification of the material changes; 2) an assessment of whether other
systems, processes, policies, and procedures previously reported did not materially change; and 3)
a review of the systems, processes, policies, and procedures that materially changed. The IRO shall
conduct the Promotional and Product Services Transactions Review for each Reporting Period of the
CIA.

			
	II.	 	Promotional and Product Services Systems Review

			
	A.	 	Description of Reviewed Policies and Procedures

The Promotional and Product Services Systems Review shall be a review of Lilly’s systems,
processes, policies, and procedures (including the controls on those systems, processes, policies,
and procedures) relating to certain Promotional and Product Services Related Functions. Where
practical, Lilly personnel may compile documentation, schedule and organize interviews, and
undertake other efforts to assist the IRO in performing the Systems Review. The IRO is not

Appendix B

Eli Lilly, Inc. CIA

1

 

required to undertake a de novo review of the information gathered or activities undertaken by
Lilly pursuant to the preceding sentence.

Specifically, the IRO shall review Lilly’s systems, processes, policies, and procedures
associated with the following (hereafter “Reviewed Policies and Procedures”):

1) Lilly’s systems, policies, processes, and procedures applicable to the
manner in which Lilly sales representatives and account executives handle and submit
requests or inquiries to The Lilly Answers Center (“TLAC”) relating to information
about the uses of Lilly’s Government Reimbursed Products (including non-FDA-approved
(i.e., off-label) uses) and the dissemination of materials relating to off-label
uses of Lilly’s Government Reimbursed Products. This review includes:

	 	a)	 	the manner in which Lilly sales
representatives and account executives handle and submit requests for
information about off-label uses of Lilly’s Government
Reimbursed Products to TLAC;
	 
	 	b)	 	the manner in which TLAC personnel, handle
and respond to requests submitted by sales representatives
and account executives for information about off-label
uses of Lilly’s Government Reimbursed Products
(including tracking the requests and using pre-approved materials for purposes of responding to the
request);
	 
	 	c)	 	the form and content of information and
materials related to Lilly’s Government Reimbursed Products
disseminated to physicians, pharmacists, or other
health care professionals (collectively “HCPs”) or
health care institutions (HCIs) by Lilly;
	 
	 	d)	 	Lilly’s systems, processes, and procedures (including
the TLAC Database) used to track requests for information submitted by sales representatives and account
executives to TLAC about off-label uses of Lilly’s Government
Reimbursed Products and responses to those requests;
	 
	 	e)	 	the manner in which Lilly collects and
supports information reported in any systems used to track and
respond to requests for product information, including
the TLAC Database;

     Appendix B

     Eli Lilly, Inc. CIA

2

 

	 	f)	 	the processes and procedures by which TLAC and
Lilly’s Compliance Office or their designee monitor
and identify situations in which it appears that
improper off-label promotion may have occurred; and
	 
	 	g)	 	Lilly’s processes and procedures for
investigating, documenting, resolving, and taking appropriate disciplinary action for potential situations involving off-label
promotion;

2) Lilly’s policies and procedures applicable to the manner and
circumstances under which its Medical Liaisons and Outcomes Liaisons participate in
meetings or events with HCPs or HCIs (either alone or with sales representatives or
account executives) and the role of the Medical Liaisons and Outcomes Liaisons at
such meetings or events, including use of the Eli Lilly Contact Information
Management (ELCIM) system to document requests and/or the use of LillyMedical.com to
respond to requests for medical information;

3) Lilly’s systems, policies, processes, and procedures relating to
Lilly’s internal review and approval of information and materials
related to Lilly’s Government Reimbursed Products disseminated to
HCPs or HCIs by Lilly;

4) Lilly’s systems, polices, processes and procedures relating to
incentive compensation for Covered Persons who are sales
representatives, with regard to whether the systems, policies,
processes, and procedures are designed to ensure that financial
incentives do not inappropriately motivate such individuals to engage
in the improper promotion, sales, and marketing of Lilly’s
Government Reimbursed Products. This shall include a review of the
bases upon which compensation is determined and the extent to
which compensation is based on product performance;

5) Lilly’s systems, processes, policies, and procedures relating to
the development and review of call plans for Lilly’s Government Reimbursed Products.
This shall include a review of the bases upon which HCPs and HCIs belonging to
specified medical specialties are included in, or excluded from, the call plans
based on expected utilization of Lilly Government Reimbursed Products for
FDA-approved uses or non-FDA-approved uses; and

6) Lilly’s systems, processes, policies, and procedures relating to the
development, implementation, and review of Sample Distribution

Appendix B

Eli Lilly, Inc. CIA

3

 

Plans. This shall include a review of the bases upon, and circumstances under, which
HCPs and HCIs belonging to specified medical specialties or types of clinical
practice may receive samples from Lilly (including, separately, from Lilly sales
representatives and Lilly’s medical services department).

B. Promotional and Product Services Systems Review Report

     The IRO shall prepare a report based upon each Systems Review. For each of the Reviewed
Policies and Procedures identified in 
Section II.A above, the report shall include the following
items:

1) a description of the documentation (including policies)
reviewed and any personnel interviewed;

2) a detailed description of Lilly’s systems, policies, processes,
and procedures relating to the items identified in Sections II.A.1-6
above, including a general description of Lilly’s control and
accountability systems (e.g., documentation and approval
requirements, and tracking mechanisms) and written policies
regarding the Reviewed Policies and Procedures;

3) a description of the manner in which the control and
accountability systems and the written policies relating to the items
identified in Sections II.A.1-6 above are made known or
disseminated within Lilly;

4) a detailed description of any system(s) used to track and
respond to requests for information submitted by sales
representatives and account executives about Lilly’s Government
Reimbursed Products (including the TLAC Database);

5) a detailed description of Lilly’s incentive compensation
system for Covered Persons who are sales representatives, including
a description of the bases upon which compensation is determined and the extent to
which compensation is based on product performance. To the extent that Lilly may
establish compensation differently for individual products, the IRO shall report
separately on each such type of compensation arrangement;

6) findings and supporting rationale regarding any weaknesses
in Lilly’s systems, processes, policies, and procedures relating to the
Reviewed Policies and Procedures, if any; and

Appendix B

Eli Lilly, Inc. CIA

4

 

7) recommendations to improve any of the systems, policies, processes, or
procedures relating to the Reviewed Policies and Procedures, if any.

			
	III.	 	Promotional and Product Services Transaction Review

           As described more fully below in Sections III.A-E, the Promotional and Product Services
Transactions Review shall include: (1) a review of a sample of Inquiries reflected in the TLAC
Database; (2) a review of Lilly’s call plans and Lilly’s call plan review process; (3) a review of
Sampling Events as defined below in Section III.C; (4) a review of records relating to a sample of
the Payments that are reported by Lilly pursuant to Section III.M of the CIA; and (5) a review of
up to three additional items identified by the OIG in accordance with Section III.D.1.b of the CIA
(hereafter “Additional Items”.) The IRO shall report on all aspects of its reviews in the
Promotional and Product Services Transactions Review Reports.

			
	A.	 	Review of Inquiries and TLAC Database

	 	1)	 	Description of TLAC Database
	 
	 	 	 	As set forth in Section III.B.3.e of the CIA, Lilly shall establish a
database (hereafter, “TLAC database”) to track information relating
to requests for information submitted by Lilly sales representatives
and account executives to TLAC about its products (hereafter
“Inquiries”). Specifically, Lilly shall document and record all
Inquiries submitted based on requests from HCPs or HCIs regarding
Lilly’s Government Reimbursed Products in the TLAC database.
Lilly shall record in the TLAC Database the following information
for each Inquiry received: 1) date of Inquiry; 2) form of Inquiry
(e.g., fax, phone, medical information request form); 3) name of
requesting HCP or HCI, in accordance with applicable privacy laws;
4) nature and topic of request (including exact language of the
Inquiry if made in writing); 5) nature/form of the response from Lilly (including a
record of any materials provided in response to the request); and 6) the name of
the Lilly representative who called upon or interacted with the HCP or HCI, if
known.
	 
	 	2)	 	Internal Review of TLAC Database
	 
	 	 	 	On a semi-annual basis, the Lilly’s Compliance Office or designee shall review the
TLAC Database and related information, as

Appendix B

Eli Lilly, Inc. CIA

5

 

appropriate, and shall generate a report summarizing the items of information
outlined in Section III.A.1 above for each Inquiry received during the preceding
two quarters (“TLAC Database Report”). Lilly’s Compliance Office or designee shall
review the TLAC Database Reports to assess whether the information contained in the
report suggests that improper off-label promotion may have occurred in connection
with any Inquiry(ies). If the Lilly’s Compliance Office or designee, in
consultation with other appropriate Lilly personnel, suspects that improper
off-label promotion may have occurred in connection with any Inquiry, the Lilly’s
Compliance Office or designee shall undertake a follow-up review of the Inquiry
(hereafter “Off-Label Review”), make specific findings based on the Off-Label
Review, and take all appropriate corrective action (including disciplinary action
of the Covered Person and reporting of the conduct, including disclosing Reportable
Events pursuant to Section III.H of the CIA, if applicable).

	 	3)	 	IRO Review of Inquiries Reflected in the TLAC Database
	 
	 	 	 	The IRO shall select and review a random sample of 60 Inquiries from among the
Inquiries reflected in the TLAC Database for each Reporting Period. Forty-five of
the Inquiries reviewed by the IRO shall be Inquiries for which Lilly conducted an
Off-Label Review, and the other 15 shall be Inquiries for which Lilly did not
conduct an Off-Label Review. If Lilly conducted an Off-Label Review on fewer than
45 Inquiries, additional Inquiries may be selected for which an Off-Label Review
was not conducted to reach a total of 60 Inquiries. For each Inquiry reviewed, the
IRO shall determine:

	 	a)	 	Whether each item of information listed above in Section
III.A.1
is reflected in the TLAC Database for each reviewed Inquiry; and
	 
	 	b)	 	For each Inquiry for which Lilly’s Compliance Office or designee
conducted an Off-Label Review, the basis for suspecting that
improper off-label promotion may have occurred; the steps undertaken as part of
the Off-Label Review; the findings of the Lilly’s Compliance Office or designee
as a result of the Off-Label Review; and any follow-up actions taken by Lilly
based on the Off-Label Review findings.

			
	B.	 	IRO Review of Lilly’s Call Plans and Call Plan Review Process

Appendix B

Eli Lilly, Inc. CIA

6

 

     The IRO shall conduct a review and assessment of Lilly’s review of its call plans for
Government Reimbursed Products as set forth in Section III.B.3.g of the CIA. Lilly shall provide
the IRO with: i) a list of products promoted by Lilly during the Reporting Period; ii) information
about the FDA-approved uses for each Lilly product; and iii) the call plans for each product. Lilly
shall also provide the IRO with information about the reviews of call plans that Lilly conducted
during the Reporting Period and any modifications to the call plans made as a result of Lilly’s
reviews.

     For each call plan, the IRO shall select a sample of 50 of the HCPs and HCIs included on the
call plan. For each call plan, the IRO shall compare the sampled HCPs and HCIs against the criteria
(e.g., medical specialty or practice area) used by Lilly in conducting its review and/or
modification of the call plan in order to determine whether Lilly followed its criteria and
Policies and Procedures in reviewing and modifying the call plan.

     The IRO shall note any instances in which it appears that the sampled HCPs and HCIs on a
particular call plan are inconsistent with Lilly’s criteria relating to the call plan and/or
Lilly’s Policies and Procedures. The IRO shall also note any instances in which it appears that
Lilly failed to follow its criteria or Policies and Procedures.

		
	C.	    IRO Review of the Distribution of Samples of Lilly’s Government Reimbursed
Products

     The IRO shall conduct a review and assessment of the distribution of samples of Lilly’s
Government Reimbursed Products to HCPs and HCIs. Lilly shall provide the IRO with: i) a list of
products for which Lilly distributed samples during the Reporting Period; ii) information about the
FDA-approved uses for each Lilly product; and iii) information about Lilly’s policies and
procedures relating to the distribution of samples of each type of product, including Lilly’s
Sample Distribution Plan showing which type samples may be distributed by sales representatives to
HCPs and HCIs of particular medical specialties or types of clinical practices. Lilly shall also
provide the IRO with information about: (1) the reviews of Sample Distribution Plans that Lilly
conducted during the Reporting Period; and (2) any modifications to the distribution plans made or
corrective actions that may be taken as a result of Lilly’s reviews, including investigating,
documenting, resolving, and taking disciplinary action.

     For each product for which Lilly distributed samples during the Reporting Period, the IRO
shall randomly select a sample of 50 separate instances in which Lilly provided samples of the
product to HCPs or HCIs either through sales

Appendix B

Eli Lilly, Inc. CIA

7

 

representation distribution or direct shipment. Each such instance shall be known as a “Sampling
Event.”

     For each Sampling Event, the IRO shall review all documents and information relating to the
distribution of the sample to the HCP or HCI, including the sample card, direct shipment request
form and/or the electronic call record. The reviewed materials shall include information about the
following: 1) the quantity, dosage, and form of the Lilly product provided to the HCP or HCI; 2)
the identity and type of medical specialty or clinical practice of the HCP or HCI; 3) which
individual Lilly sales representative accepted the sample request form or provided the sample to
the HCP or HCI; 4) the manner and mechanism through which the sample was requested (e.g., sample
card or direct shipment request form); and 5) the manner and mechanism through which the request
was fulfilled (e.g., sales representative distribution or direct shipment.)

     For each Sampling Event, the IRO shall evaluate whether the sample was provided to an HCP or
HCI whose medical specialty or clinical practice is consistent with the uses of the product
approved by the FDA and whether the sample was distributed by a Lilly representative in a manner
consistent with Lilly’s sample distribution policy for the product(s) provided during the Sampling
Event. To the extent that a sample was provided to an HCP or HCI by a Lilly representative other
than a sales representative, the IRO shall contact the HCP or HCI by letter. The letter shall
request that the HCP or HCI: 1) verify that he/she/it received the quantity and type of samples
identified by the IRO as the Sampling Event; 2) verify that he/she/it requested the samples
provided during the Sampling Event; 3) explain or confirm its type of medical specialty or clinical
practice; and 4) identify the basis for requesting the sample (e.g., conversations with a Lilly
sales representative, conversation with a representative of Lilly’s medical services department,
independent research or knowledge of the HCP or HCI, etc.)

     For each Sampling Event, the IRO shall compare the medical specialty and type of clinical
practice of the HCPs and HCIs that received the sample with uses of the product approved by the
FDA. The IRO shall note any instances in which it appears that the medical specialty or clinical
practice of the HCPs or HCIs that received a sample during a Sampling Event were not consistent
with the uses of the product approved by the FDA. For each such situation, the IRO shall note the
process followed by Lilly in determining that it was appropriate to provide a sample to such HCP or
HCI and the basis for such determination. For each Sampling Event, the IRO shall also note any
instances in which it appears that Lilly failed to follow its Sample Distribution Plan and sample
policies and procedures for the product(s) provided during the Sampling Event and, if so, whether
Lilly already had taken corrective action, including investigating, documenting, resolving, and
taking disciplinary action, if appropriate.

Appendix B

Eli Lilly, Inc. CIA

8

 

			
	D.	 	IRO Review of Physician Payment Listings

	 	1)	 	Information Contained in Physician Payment Listings

         As set forth in Section III.M of the CIA, Lilly shall post quarterly and annual listings of
physicians and Related Entities who received Phase I, II, or III Payments, as defined in the CIA,
directly or indirectly from Lilly. For purposes of the IRO review as set forth in this Section
III.C, each annual listing shall be referred to as the “Physician Payment Listing” or “Listing.”
For each physician and Related Entity, each Physician Payment Listing shall include the following
information: i) physician’s full name; ii) name of Related Entity (if applicable); iii) city and
state that the physician or the Related Entity has provided to Lilly for contact purposes; and (iv)
the aggregate value of the payment(s) in the preceding quarter(s) or year (as applicable). If
payments for multiple physicians have been made to one Related Entity, the aggregate value of all
payments to the Related Entity will be the reported amount.

         For purposes of this IRO review, the term “Control Documents” shall include all documents or
electronic records associated with each Payment reflected in the Physician Payments Listing for the
sampled physician and/or Related Entity. For example, the term “Control Documents” includes, but is
not limited to, documents relating to the nature, purpose, and amount of all Payments reflected in
the Listing; contracts relating to the Payment(s) reflected in the Listing; documents relating to
the occurrence of Payment(s) reflected in the Listing; documents reflecting any work product
generated in connection with the Payment(s); documents submitted by sales representatives or
headquarters personnel to request approval for the Payment(s); and business rationale or
justification forms relating to the Payment(s).

	 	2)	 	Selection of Sample for Review

         For each Reporting Period, the OIG shall have the discretion to identify up to 50 physicians
or Related Entities from the applicable Physician Payment Listing that will be subject to the IRO
review described below. If the OIG elects to exercise this discretion, it shall notify the IRO of
the physicians and/or Related Entities subject to the IRO review. If the OIG elects not to exercise
its discretion as described above, the IRO shall randomly select 50 physicians and/or Related
Entities to be included in the review. For each selected physician and/or Related Entity, the IRO
shall review the entry in the Physician Payment Listing and the Control Documents relating to
Payments reflected in Listing identified by the IRO as necessary and sufficient to validate the
Payment information in the Listing.

Appendix B

Eli Lilly, Inc. CIA

9

 

	 	3)	 	IRO Review of Control Documents for Selected Physicians
and/or Related Entities

     For each physician and/or Related Entity selected as part of the sample, the IRO shall review
the Control Documents identified by the IRO as necessary and sufficient to validate each Payment
reflected in the Listing to evaluate the following:

	 	a)	 	Whether Control Documents are available relating to each
Payment reflected in the Listing for the sampled physician
and/or Related Entity;
	 
	 	b)	 	Whether the Control Documents were completed and
archived in accordance with the requirements set forth in
Lilly’s policies;
	 
	 	c)	 	Whether the aggregate value of the Payment(s) as reflected in
the Listing for the sampled physician or Related Entity is
consistent with the value of the Payments(s) reflected in the
Control Documents; and
	 
	 	d)	 	Whether the Control Documents reflect that
Lilly’s policies were followed in connection with Payment(s)
reflected in the Listing (e.g., all required written approvals for
the activity were obtained in accordance with Lilly’s
policies.)

	 	4)	 	Identification of Material Errors and Additional Review
	 
	 	 	 	A Material Error is defined as any of the following:

	 	a)	 	A situation in which all required Control Documents relating to
Payments reflected in the Listing for the sampled physician
and/or Related Entity do not exist and:

	 	i.	 	no corrective action was initiated prior to the selection of
the sampled physicians and/or Related Entities; or
	 
	 	ii.	 	the IRO cannot confirm that Lilly otherwise
followed its policies and procedures relating to the entry in
the Listing for the sampled physician or Related Entity,
including its policies and procedures relating to any
Payment(s) reflected in the Listing; or

Appendix B

Eli Lilly, Inc. CIA

10

 

	 	b)	 	Information or data is omitted from key fields in the Control Documents that
prevents the IRO from assessing compliance with Lilly’s policies and
procedures, and the IRO cannot obtain this information or data from reviewing
other Control Documents.

     If a Control Document does not exist, but Lilly has initiated corrective action prior to the
selection of the sampled physicians and/or Related Entities, or if a Control Document does not
exist but the IRO can determine that Lilly otherwise followed its policies and procedures with
regard to each entry in the Listing for a sampled physician or Related Entity, the IRO shall
consider such a situation to be an exception (rather than a Material Error) and the IRO shall
report the situation as such. The IRO shall note as exceptions any Control Documents for which
non-material information or data is omitted.

     If the IRO identifies any Material Errors, the IRO shall conduct such Additional Review of the
underlying Payment associated with the erroneous Control Documents as may be necessary to determine
the root cause of the Material Errors. For example, the IRO may need to review additional
documentation and/or conduct interviews with appropriate personnel to identify the root cause of
the Material Error(s) discovered.

			
	E.	 	IRO Review of Additional Items

     As set forth in Section III.D.1.b of the CIA, for each Reporting Period, the OIG at its
discretion may identify up to three additional items for the IRO to review (hereafter “Additional
Items”.) No later than 120 days prior to the end of the applicable Reporting Period, the OIG shall
notify Lilly of the nature and scope of the IRO review to be conducted for each of the Additional
Items. Prior to undertaking the review of the Additional Items, the IRO and/or Lilly shall submit
an audit work plan to the OIG for approval and the IRO shall conduct the review of the Additional
Items based on a work plan approved by the OIG. The IRO shall include information about its review
of each Additional Item in the Transactions Review Report (including a description of the review
conducted for each Additional Item; the IRO’s findings based on its review for each Additional
Item; and the IRO’s recommendations for any changes in Lilly’s systems, processes, policies, and
procedures based on its review of each Additional Item.)

     Lilly may propose to the OIG that its internal audit(s) and/or reviews conducted as part of
the Lilly Compliance Monitoring Program be partially substituted for one or more of the
Additional Items that would otherwise be reviewed by the IRO for the applicable Reporting
Period. The Lilly Compliance

Appendix B

Eli Lilly, Inc. CIA

11

 

Monitoring Plan is a monitoring plan developed by Lilly’s Compliance Office that includes the
following types of events: Advisory Board Meetings, Consultant Task Force Activities, Speaker
Trainings, Speaker Programs, Exhibits, Internal Meetings, Field Sales Meetings, Sales
Representative Ride-Alongs, Medical or Outcome Liaison Ride-Alongs, Good Business Practice Reviews,
Grant Committee Meetings, and Activities Funded by Lilly Grant Office. The OIG retains sole
discretion over whether, and in what manner, to allow Lilly’s internal audit work to be substituted
for a portion of the Additional Items review conducted by the IRO.

     In making its decision, the OIG agrees to consider, among other factors, the nature and scope
of Lilly’s planned internal audit work and/or reviews conducted under the Compliance Monitoring
Program, the results of the Transactions Review(s) during prior Reporting Period(s), and Lilly’s
demonstrated audit capabilities to perform the proposed audit work internally. If the OIG denies
Lilly’s request to permit its internal audit work to be substituted for a portion of the IRO’s
review of Additional Items in a given Reporting Period, Lilly shall engage the IRO to perform the
Review as outlined in this Section III.

     If the OIG agrees to permit certain of Lilly’s internal audit work for a given Reporting
Period to be substituted for a portion of Additional Items review, such internal work would be
subject to verification by the IRO (Verification Review). In such an instance, the OIG would
provide additional details about the scope of the Verification Review to be conducted by the IRO.
However, for purposes of any Verification Review, the IRO shall review of at least 20% of the
sampling units reviewed by Lilly in its internal audits.

			
	F.	 	Promotional and Product Services Transactions Review Report

     For each Reporting Period, the IRO shall prepare a report based on its Promotional and Product
Services Transactions Review. The report shall include the following:

	 	1) 	 	 General Elements to Be Included in Report

	 	a)	 	Review Objectives: A clear statement of the
objectives intended to be achieved by each part of the review;
	 
	 	b)	 	Review Protocol: A detailed narrative description of the
procedures performed and a description of the sampling unit
and universe utilized in performing the procedures for each
sample reviewed; and

Appendix B

Eli Lilly, Inc. CIA

12

 

	 	c)	 	Sources of Data: A full description of documentation and other
information, if applicable, relied upon by the IRO in performing the
Promotional and Product Services Transactions Review.

	 	2)	 	Results to be Included in Report
	 
	 	 	 	The following results shall be included in each Promotional and Product
Services Review Report:
	 
	 	 	 	(Relating to the Review of Inquiries)

	 	a)	 	in connection with the review of Inquiries, a description of
each type of sample unit reviewed, including the number of
each type of sample units reviewed (e.g., the number of
Inquiries) and an identification of the types of documents and
information reviewed for the Inquiries;
	 
	 	b)	 	for each Inquiry sample unit, the IRO shall summarize the
information about the Inquiry contained in the TLAC
Database;
	 
	 	c)	 	for each Inquiry sample unit, findings and supporting
rationale as to whether: (i) each item of information listed in
Section III.A.1 is reflected in the TLAC Database; and (ii) for
each Inquiry for which an Off-Label Review was conducted,
the basis for suspecting that improper off-label promotion
may have occurred; the steps undertaken as part of the Off-Label Review; the findings of Lilly’s Compliance Office as a
result of the Off-Label Review; and any follow-up actions
taken by Lilly as a result of Lilly’s Compliance Office
findings;
	 
	 	d)	 	the findings and supporting rationale regarding any
weaknesses in Lilly’s systems, processes, policies, procedures, and
practices relating to the Inquiries, and the TLAC Database, if any;
	 
	 	e)	 	recommendations for improvement in Lilly’s systems,
processes, policies, procedures, and practices relating to the Inquiries
and the TLAC Database, if any;

(Relating to the Call Plan Reviews)

Appendix B

Eli Lilly, Inc. CIA

13

 

	 	f)	 	a list of the Government Reimbursed Products promoted by Lilly
during the Reporting Period and a summary of the FDA-approved uses for such
products;
	 
	 	g)	 	for each Lilly Government Reimbursed Product: i) a
description of the criteria used by Lilly in developing or reviewing the
call plans and for including or excluding specified types of HCPs or HCIs
from the call plans; ii) a description of the review conducted by Lilly of
the call plans and an indication of whether Lilly reviewed the call plans
as required by Section III.B.3.g of the CIA; iii) a description of all
instances for each call plan in which it appears that the HCPs and HCIs
included on the call plan are inconsistent with Lilly’s criteria relating
to the call plan and/or Lilly’s Policies and Procedures; and iv) a
description of all instances in which it appears that Lilly failed to
follow its criteria or Policies and Procedures relating to call plans or
the review of the call plans;
	 
	 	h)	 	the findings and supporting rationale regarding any
weaknesses in Lilly’s systems, processes, policies, procedures, and practices
relating to Lilly’s call plans or the review of the call plans, if any;
	 
	 	i)	 	recommendations, if any, for changes in Lilly’s
systems, processes, policies, procedures, and practices that would correct or
address any weaknesses or deficiencies uncovered during the Transactions
Review with respect to call plans or the review of the call plans;

(Relating to the Sampling Event Reviews)

	 	j)	 	for each Lilly product distributed during the Reporting
Period: i) a description of Sample Distribution Plan (including whether
sales representatives may provide samples of the product and, if so, to
HCPs or HCIs of which medical specialty or type of clinical practice a
sales representative may provide samples); ii) a detailed description of
any instances from the reviews by the IRO in which it appears that the
medical specialty or clinical practice of the HCPs or HCIs that received a
sample during a Sampling Event were not consistent with the uses of the
product approved by the

Appendix B

Eli Lilly, Inc. CIA

14

 

FDA. This description shall include a description of the process followed
by Lilly in determining that it was appropriate to provide a sample to such
HCP or HCI and the basis for such determination; and iii) a detailed
description of any instances in which it appears that Lilly failed to
follow its Sample Distribution Plan for the product(s) provided during the
Sampling Event;

	 	k)	 	the findings and supporting rationale regarding any
weaknesses in Lilly’s systems, processes, policies, procedures, and practices
relating to Lilly’s distribution of samples of Lilly’s Government Reimbursed
Products, if any;
	 
	 	l)	 	recommendations, if any, for changes in Lilly’s
systems, processes, policies, procedures, and practices that would correct or
address any weaknesses or deficiencies uncovered during the Transactions
Review with respect to the distribution of samples;

(Relating to the Physician Payment Listing Reviews)

	 	m)	 	a description of the entries in the Physician Payment
Listing for each physician or Related Entity sampled and a description of
Control Documents reviewed in connection with each selected physician or
Related Entity;
	 
	 	n)	 	for each sampled physician or Related Entity, findings and
supporting rationale as to whether: (i) all required Control
Documents exist; (ii) each Control Document was completed
in accordance with all of the requirements set forth in the
applicable Lilly policy; (iii) the aggregate value of the
Payment(s) as reflected in the Listing for the sampled
physician or entity is consistent with the value of the
Payment(s) reflected in the Control Documents; (iv) each
Control Document reflects that Lilly’s policies were followed in
connection with the underlying activity reflected in the document
(e.g.,
all required approvals were obtained); and (v) any corrective action or
disciplinary action was undertaken in those instances in which Lilly
policies were not followed;
	 
	 	o) 	 	 for each sampled physician or Related Entity unit
reviewed, an identification and description of all exceptions discovered. The
report shall also describe those instances in which

Appendix B

Eli Lilly, Inc. CIA

15

 

corrective action was initiated prior to the selection of the sampled
physicians or Related Entities, including a description of the
circumstances requiring corrective action and the nature of the corrective
action;

	 	p)	 	if any Material Errors are discovered in any sample unit
reviewed, a description of the error, the Additional Review procedures
performed and a statement of findings as to the root cause(s) of the
Material Error;

(Relating to the Review of Additional Items)

	 	q)	 	for each Additional Item reviewed, a description
of the review conducted;
	 
	 	r)	 	for each Additional Item reviewed, the IRO’s findings
based on its review;
	 
	 	s)	 	for each Additional Item reviewed, the findings and
supporting rationale regarding any weaknesses in Lilly’s systems,
processes, policies, procedures, and practices relating to the
Additional Item, if any; and
	 
	 	t)	 	for each Additional Item reviewed, recommendations, if
any, for changes in Lilly’s systems, processes, policies, and procedures that
would correct or address any weaknesses or deficiencies uncovered during the
review.

Appendix B

Eli Lilly, Inc. CIA

16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}]]